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ABSTRACT 
Since little is known about the contribution of B cells to the pathology of psoriatic 
arthritis (PsA), this study investigated the possible recruitment of peripheral blood B cells 
to sites of inflammation by differential expression of chemokine receptors CXCR3, 
CXCR4, CXCR5, CCRl , CCR2, CCR5 and CCR6. Secondly, we explored the role of 
B cell activating factor (BAFF) in PsA. The chemokine receptor expression analysis did 
not reveal any significant differences (p-values >0.05 for all receptors) both at the RNA 
and the protein level when comparing PsA patients (n = 13) to rheumatoid arthritis (RA) 
patients (n = 15) and healthy controls (n = 1 0). Also, there was no significant difference 
(p = 0.1291) in plasma BAFF levels between PsA (n = 37) or RA patients (n = 24) and 
healthy controls (n = 35). Our study does not provide supporting evidence of B cell 
involvement in PsA, however it was limited to the analysis of peripheral blood. 
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CHAPTER 1 
INTRODUCTION 
1.1 PSORIATIC ARTHRITIS 
1.1.1 Defining psoriatic arthritis 
Psoriatic arthritis (PsA) is an inflammatory arthritis that is associated with psoriasis. The 
association between psoriasis and arthritis was first described by Alibert in 1818 but not 
until 1964 was Psoriatic arthritis recognized as a distinct disease entity by the American 
Rheumatism Association (Tam and Geier 2004). Today PsA is considered a subtype of 
spondyloarthritis, a group of related rheumatic diseases, which includes for example 
ankylosing spondylitis, reactive arthritis or arthritis of inflammatory bowel disease. They 
share certain clinical features such as inflammatory spinal pain and they are associated 
with the HLA-B27 allele (Hochberg 2003). To distinguish PsA from related diseases, the 
classification criteria developed by Moll and Wright have been traditionally used. A 
patient must have psoriasis and an inflammatory form of arthritis while being negative 
for rheumatoid factor and must present with one of the following clinical subtypes: 1) 
Polyarticular, symmetric arthritis (rheumatoid arthritis-like), 2) Oligoarticular (<5 
affected joints), asymmetric arthritis, 3) distal interphalangeal (DIP) 1 joint predominant, 
4) spondylitis2 predominant or 5) arthritis mutilans3 (Moll and Wright 1973). The 
heterogeneous picture of PsA however makes it still difficult to diagnose and research the 
1 DIP joints are the joints on fingers and toes closest to the nail 
2 Spondylitis describes an inflammation of one or more vertebrae 
3 Arthritis mutilans is a severe form of arthritis with destruction of joint cartilages and bony surfaces 
leading to deformities on mainly hands and feet 
2 
disease. Therefore the CASPAR (Classification criteria for Psoriatic Arthritis) group has 
recently developed a new classification system. This study group is the result of an 
international collaboration and the new criteria were based on a large study including 30 
clinics in 13 countries. The CASPAR criteria are summarized in Table 1.1. These new 
criteria for PsA have better specificity, but less sensitivity than other criteria developed 
and are therefore beneficial for use in clinical research (Taylor, Gladman eta!. 2006). 
Moreover, the CASPAR criteria reflect the specific features of spondyloarthritis that 
makes it differ from other forms of inflammatory arthritis such as RA. Dactylitis for 
example is common in PsA and occurs in about 30% to 40% of patients (Hochberg 
2003). Another hallmark is the inflammation at the enthesis4 that occurs in 20% to 40% 
of PsA patients. A further prominent feature is the destruction of the nail (nail 
dystrophy5). Nail dystrophy is associated with joint involvement and is more common in 
patients with PsA than in patients with uncomplicated psoriasis. There is no correlation 
however between the severity of the skin disease and joint scores, still 30% to 40% of 
patients experience coincidental flares of skin disease arthritis. 
4 Enthesis is the location where the tendon inserts into the bone 
5 Nail dystrophy is the chronic destruction of the nail plate and includes here detachment of the nail from 
the nail bed, pitting of the nail and hyperkeratos is 
3 
Table 1.1: Summary of CASPAR criteria for PsA. 
To meet the CASPAR criteria a patient must have inflammatory articular disease Uoint, 
spine or entheseal) with ~3 points from the following 5 categories: 
1. Evidence of current psoriasis, a personal history of psoriasis, or a family history 
of psoriasis (current psoriasis is defined as psoriatic skin or scalp disease present 
today as judged by a rheumatologist or dermatologist6. A personal history of 
psoriasis is defined as a history of psoriasis that may be obtained from a patient, 
family physician, dermatologist, rheumatologist, or other qualified health care 
provider. A family history of psoriasis is defined as a history of psoriasis in a 
first- or second-degree relative according to patient report.). 
2. Typical psoriatic nail dystrophy including onycholysis7 pitting, and 
hyperkeratosis observed on cuiTent physical examination. 
3. A negative test result for the presence of rheumatoid factor by any method except 
latex but preferably by enzyme-linked immunosorbent assay or nephelometry, 
according to the local laboratory reference range. 
4. Either current dactylitis, defined as swelling of entire digit, or a history of 
dactylitis recorded by a rheumatologist. 
5. Radiographic evidence of juxtaarticular new bone formation appearmg as ill-
defined ossifications8 near joint margins (but excluding osteophyte9 formation) on 
plain radiographs of the hand or foot. 
From Taylor, Gladman eta!. 2006. 
6 Current psoriasis is assigned a score of2; all other features are assigned a score of I 
7 Onycholysis is a loosening of the exposed portion of the nai l from the nai l bed 
8 Ossification is the process of creating bone 
9 Osteophyte is a small bony outgrowth 
4 
1.1.2 Epidemiology 
Even though some patients with psoriasis could have coincidental rheumatoid arthritis 
(RA) epidemiological evidence supports the concept of PsA as distinct disease entity 
(Tam and Geier 2004; Gladman, Antoni et al. 2005). The prevalence of psoriasis in the 
general population is 2% to 3% while it occurs in 7% of arthritis patients. PsA is 
prevalent in 6% to 42% of psoriasis patients whereas only 2% to 3% of the general 
population present with an inflammatory arthritis (Gladman, Antoni et al. 2005). This 
variance in prevalence estimates for PsA in psoriasis patients are most likely due to the 
heterogeneity of the disease and the lack of validated diagnostic criteria available at the 
time (Cassell and Kavanaugh 2005). 
In contrast to RA, which has a female predominance, PsA affects men and women 
equally. The onset of disease occurs between 30 and 55 years of age. The majority of 
patients (70%) have psoriasis before developing PsA. In the remainder of patients the two 
conditions either occur at the same time (15%) or arthritis precedes the onset of PsA 
(15%) (Hochberg 2003). 
1.1.3 Pathogenesis 
The cause of PsA is not known but it is believed that genetic, immunological and 
environmental factors play a role. Additionally, a distinctive vascularity as well as bone 
remodeling contribute to the features seen in PsA pathology. It is similar to RA but there 
are unique features that set PsA apart as a distinct disease entity. 
5 
a) Genetics 
There is compelling evidence that PsA has a strong genetic component. Actually 40% of 
PsA patients have a first-degree relative with either psoriasis or PsA (Cassell and 
Kavanaugh 2005; Turkiewicz and Moreland 2007). Several genetic susceptibility loci 
have been reported and the strongest association has been made with the major 
histocompatibility complex (MHC) region. Population studies have shown an increased 
frequency for the MHC class I alleles HLA-B27, HLA-B38, HLA-B39 and HLA-Cw6 in 
PsA patients. HLA-B27 is associated predominantly with spinal disease and the allele is 
typical of a spondyloarthritis, as mentioned earlier. On the other hand, alleles HLA-B38 
and HLA-B39 are more frequent in patients with peripheral polyarthritis (Rahman and 
Elder 2005). The MHC class II allotype HLA-DR4 is also linked to peripheral arthritis in 
PsA patients (Cassell and Kavanaugh 2005). In psoriasis, the MHC class I alleles HLA-
BIJ and HLA-B17 have been linked to disease as well as HLA-Cw6 (Veale and 
FitzGerald 2002; Rahman and Elder 2005). In PsA patients, HLA-Cw6 is linked to an 
earlier age of onset for their psoriasis (Gladman, Cheung et al. 1999). The importance of 
the MHC region for PsA is further supplemented by linkage studies. A sibling pair 
analysis for PsA suggested higher HLA haplotype sharing among siblings that are both 
affected by PsA (Gladman, Farewell et al. 2003). And from the eight susceptibility loci 
for psoriasis (PSORS 1-7 and PSORS9), the most important susceptibility locus PSORS 1 
falls within the MHC (Schon and Boelmcke 2005). 
Non-HLA genes within the MHC have been investigated as well. A TNF-a promoter 
polymorphism or a gene in linkage disequilibrium with TNF-a may contribute to 
6 
predisposition to psoriasis and PsA (Veale and FitzGerald 2002; Cassell and Kavanaugh 
2005; Turkiewicz and Moreland 2007). The MHC class I chain - related A (MICA)-A9 
polymorphism is another susceptibility factor in PsA (Gonzalez, Martinez-Berra et al. 
2002). Outside the MHC region, IL-l has been identified as a susceptibility locus in PsA 
(Rahman, Sun et al. 2006). Furthermore, the killer immunoglobulin-like receptor 
(KIR2DSI) gene, which has HLA-C as its ligand, showed an increased frequency in PsA 
patients (Williams, Meenagh et al. 2005). Interestingly, having an affected father 
increases the probability of disease in the children as there is excessive paternal 
transmission in PsA (Rahman, Gladman et al. 1999). 
b) Immunology 
The inflammatory nature of PsA is shown both in skin and joint. Psoriatic skin is 
characterized by epidermal hyperplasia 10, infiltration of lymphoid cells and abnormalities 
in vasculature (Veale and FitzGerald 2002). The same is true for the joint with synovial 
lining hyperplasia and infiltration of lymphocytic cells in the synovium and at sites of 
entheseal involvement (Veale and FitzGerald 2002; Gladman 2005). This is similar to 
what is seen in the inflamed synovium of rheumatoid arthritis (RA) but the inflammation 
in the PsA synovium exhibits less synovial lining hyperplasia, fewer macrophages and a 
higher vascularity compared to RA (Turkiewicz and Moreland 2007). Fig. 1.1 shows the 
histological appearance of normal skin compared to a psoriatic lesion. 
10 Hyperplasia is an abnormal increase in the number of cells 
7 
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Re ti c ul a r dermis 
Figure 1.1 : Skin histology diagrams in normal skin and psoriatic plaque. 
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I 
The epidermal rete 11 become elongated and protrude into the dermis (Lowes, Bowcock et 
a!. 2007). There is increased proliferation of keratinocytes in the epidermis but these cells 
are not completely differentiated and can therefore not stack normally. This abnormality 
of the stratum corneum 12 leads to the scales typically seen in psoriatic skin (Lowes, 
Bowcock et a!. 2007). The blood vessels in the dermis are enlarged as well and stretch in 
between the epidermal rete. 
Changes in vascularity are also seen in the PsA synovmm (see 1.1.3 d) as well as 
thickening of the synovial membrane as shown in Figure 1.2. Leukocytes can enter the 
inflamed skin and joint as the activated endothelial cells express adhesion molecules to 
facilitate their transmigration. In the psoriatic skin, intercellular adhesion molecule-1 
(ICAM-1 ), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin enable 
leukocytes to enter the skin (Lowes, Bowcock et a!. 2007). The same adhesion molecules 
are expressed by endothelial cells of the synovium yet E-selectin is expressed at lower 
levels (Veale, Ritchlin et a!. 2005). 
11 Epidermal rete are downward undulations of the epidermis 
12 Stratum corneum is the outermost layer of the epidermis 
9 
Nonm1l Knee 
Joint 
Capsule 
Mild 
Inflammation 
Increased 
Angiogenesis 
Figure 1.2: Normal joint features compared to joint with early and established 
inflammation. The established inflammation shows the pannus formation and the effects 
on the bone. 
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The infiltrating leukocytes in the synovium are mainly neutrophils, macrophages and T 
cells (Kruithof, Baeten eta!. 2005). C04+ T cells are the most common lymphocyte in the 
synovium as well as the skin however COS+ T cells outnumber C04+ T cells at the 
enthesis and in the synovial fluid (Veale and FitzGerald 2002). The infiltrate in the skin is 
similar to the one in the synovium with neutrophils found in the stratum corneum and 
lymphocytes and monocytes infiltrating the dermis. T cells and dendritic cells are the 
most abundant lymphocytes in the dermis (Lowes, Bowcock et al. 2007). 
In contrast to uncomplicated psoriasis, B cells are also part of the infiltrate in the skin 
(Veale, Barnes et a!. 1994) and are commonly seen in the inflamed synovium 
(Turkiewicz and Moreland 2007). Their role in PsA is not clear, however they form 
germinal center like follicles as seen in ectopic lymphoid neogenesis (Canete, Santiago et 
a!. 2007) and seem to be antigen-activated as determined by the analysis of 
immunoglobulin heavy chain variable (IgVH) genes (Gerhard, Krenn eta!. 2002). So far, 
the focus has been on infiltrating T cells as C04+ T cells and CDS+ T cells are clonally 
expanded in the skin and synovium. COS+ T cells seem to play a role in disease 
pathogenesis since they are the most common cell found in the synovial fluid and HLA 
class I is mainly associated with PsA (Veale and FitzGerald 2002). In the psoriatic skin, 
COS+ T cells are mainly found in the epidermis as they express the ae~7 integrin which 
binds to E-cadherin on keratinocytes (Krueger 2002; Lowes, Bowcock eta!. 2007). CD4+ 
T cells outnumber the CDS+ T cells in the dermis similar to the ratio seen in peripheral 
blood. 
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Furthermore, different subsets of dendritic cells are found in the skin of psoriasis patients. 
Apart from the resident Langerhans cells there is an increase in dermal CD 11 c + dendritic 
cells (myeloid origin) in the lesion as well as mature dendritic cells as shown by CD83 or 
DC-LAMP expression (Krueger 2002). T cells and dendritic cells form aggregates, which 
most likely promote T cell activation since mature dendritic cells are potent T cell 
stimulators (Lowes, Bowcock et al. 2007). 
The mediators of these inflammatory processes are cytokines. High levels of T11 1 
cytokines TNF-a., IFN-y and IL-2 have been detected in both synovium and skin (Veale 
and FitzGerald 2002; Turkiewicz and Moreland 2007). In the synovium, the T 112 cytokine 
IL-l 0 is increased as well, but not IL-4 (Veale and FitzGerald 2002). Staining of PsA 
synovia additionally revealed expression of IL-l a., IL-l P and IL-15 (Veale and 
FitzGerald 2002). An important cytokine for disease pathogenesis is TNF -a.. It is 
produced mainly by monocytes and macrophages but also by B cells, T cells, fibroblasts 
and keratinocytes (Choy and Panayi 200 I; Mease 2006). TNF -a. together with IL-l 
activates synovial fibroblasts, osteoclasts 13 and chondrocytes 14 and additionally TNF-a. 
promotes keratinocyte survival (Mease 2006). In turn, the activated fibroblasts produce 
other inflammatory cytokines such as IL-l , IL-6 and platelet-derived growth factors 
(Gladman 2005). TNF-a. also activates endothelial cells, which in turn start expressing 
adhesion molecules to attract leukocytes to the site of inflammation as described above 
13 Osteoclast is a bone-resorbing cell 
14 Chondrocyte is a cartilage cell 
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(Choy and Panayi 2001). TNF-a. and IL-l are also responsible for joint damage (see 
1.1.3e)). 
They stimulate chondrocytes and synovial fibroblasts to release matrix metalloproteases 
that degrade connective-tissue matrix leading to cartilage erosion (Choy and Panayi 
2001; Turkiewicz and Moreland 2007). 
c) Environment 
Both infection and trauma have been suggested to trigger PsA. Infection with human 
immunodeficiency virus has also been linked to psoriasis and PsA. A study from Zambia 
for example showed that 94% of PsA patients are HIV -positive and that the arthritis 
occurs in the early stages of infection (Veale and FitzGerald 2002; Hochberg 2003). 
Another study also reported an association between hepatitis C virus (HCV) and PsA as 
higher levels of antibodies for HCV were found in sera from PsA patients compared to 
healthy controls and psoriasis patients (Veale and FitzGerald 2002). 
Physical trauma can also induce the onset of disease and this is especially known for 
psoriasis (Veale and FitzGerald 2002; Hochberg 2003; Turkiewicz and Moreland 2007). 
The Koebner phenomenon, which describes the development of psoriatic lesions at the 
site where the skin has been irritated by physical injury, has been described in a 
significant percentage of psoriasis patients. Another study reported that 24% of PsA 
patients suffered from a trauma to a joint before disease onset (Turkiewicz and Moreland 
2007). 
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d) Vascularity 
Vascular morphological changes can be seen in psoriatic skin lesions and PsA synovium 
(Veale, Yanni et al. 1993; Reece, Canete et al. 1999; Fraser, Fearon et al. 2001). They 
seem to be more important for the pathogenesis in PsA as studies by Veale state a more 
pronounced vascularity in PsA compared to RA (Veale and FitzGerald 2002). Elongated 
and tortuous vessels are characteristic for PsA synovium and skin which suggests a 
dysregulated angiogenesis resulting in new but immature vessels (Veale and FitzGerald 
2002; Veale, Ritchlin et al. 2005). Angiogenic factors are most likely responsible for this 
increase in vascularity (Veale and FitzGerald 2002; van Kuijk, Reinders-Blankert et al. 
2006). An increased expression of angiogenic growth factors such as transforming 
growth factor~ (TGF-~), platelet derived growth factor (PDGF) and vascular endothelial 
growth factor (VEGF) is found in psoriatic skin lesions. VEGF and TGF-~ are also found 
at high levels in synovial fluid of patients with early PsA suggesting that angiogenesis is 
an early event in psoriasis and PsA (Veale, Ritchlin et al. 2005). Furthermore, another 
family of vascular growth factors called angiopoietins is found in perivascular areas of 
PsA joint synovium and co-localizes with VEGF expression (Veale and FitzGerald 
2002). This increased expression of angiopoietins is supporting the role of growth factors 
as a cause for the vascular changes seen (Veale, Ritchlin et al. 2005). These similar 
findings of aberrant vascularity in both skin and joint may reflect a common 
neurovascular pathway (Veale and FitzGerald 2002). 
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e) Bone remodeling 
The effects of the inflammation on the bone can be seen as bone erosions in affected 
joints. Radiographically the affected joints show loss in joint space, bone lesions, pencil-
in-cup erosions (the bone becomes pointed and the adjacent joint looks cup-like due to 
erosions) and bone resorption (Ritchlin, Haas-Smith eta!. 2003). Unlike in RA, new bone 
formation often accompanies the bone resorption, often in the same digit and at the site of 
the entheseal inflammation (Ritchlin, Haas-Smith eta!. 2003; Walsh, Crotti eta!. 2005). 
These findings point towards a disordered pattern of bone remodeling in PsA joints and 
furthermore these erosions differ from the bone loss seen in RA (Ritchlin, Haas-Smith et 
a!. 2003). Altered signaling in osteoclast precursors is most likely responsible for the 
changes seen in PsA joints. Osteoclast precurors (OCP) are of monocyte/macrophage 
lineage and they can mature into osteoclasts, which degrade bone matrix and are the main 
cells responsible for bone resorption. In the circulation of PsA patients OCP are actually 
increased and studies in mice demonstrate that TNF-a can increase the number of 
circulating OCP (Ritchlin, Haas-Smith eta!. 2003; Colucci, Brunetti et al. 2007). Fig. 1.3 
shows the model proposed by Richtlin et a/. (Ritchlin, Haas-Smith et al. 2003) for a 
possibly altered OCP signalling that leads to the changes seen in the joint. The end result 
in their model is a bi-directional bone resorption from the inside (subchondral) of the 
bone as well as from the inflamed outside of the bone (pannus-bone interface, see also 
Figure 1.2). 
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Figure 1.3: Schematic model of osteolysis in the psoriatic joint. 
Circulating OCPs enter the synovium and become osteoclasts via RANKL signalling. 
OCPs in the subchondral bone undergo osteoclastogenesis as well. 
OC: osteoclasts; OCP: osteoclast precursor; RANKL: receptor activator ofNF-KB ligand 
From Ritchlin, Haas-Smith et at. 2003. 
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1.1.4 Treatment 
Treatment for PsA needs to address both the skin and the joint involvement. Mild to 
moderate arthritis without evidence of progressive joint damage is usually treated with 
nonsteroidal anti-inflammatory drugs (NSAIDs) (Turkiewicz and Moreland 2007). 
Traditional NSAIDs like Ibuprofen and Diclofenac are unselective and block both 
cycloogxygenase (Cox) enzymes (Cox-1 and Cox-2), which are responsible for 
promoting inflammation and pain by producing prostaglandins. While they work well to 
reduce inflan1mation and improve pain and joint mobility, some patients experience 
considerable gastrointestinal side effects (Turkiewicz and Moreland 2007). New selective 
NSAIDs like Celecoxib specifically block the Cox-2 enzyme and this results in a better 
gastrointestinal tolerance. NSAIDs, however, do not modify the course of the arthritis 
and cannot prevent progressive joint disease (Gladman 2005). About 20% of PsA patients 
develop deforming and destructive arthritis (Turkiewicz and Moreland 2007) therefore 
needing more intensive treatment. Table 1.2 shows a treatment guideline for PsA patients 
according to the symptoms presented. 
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Table 1.2: Treatment guideline for PsA patients. 
I 
Peripheral Skin and ( Axial. Disease j [ Dactylitis J Arthritis Nail Disease 
ij 
Initiate Initiate Initiate Initiate 
Therap_y: Therapy: Iherapy: Therapy: 
NSAID Toplcals NSAID NSAID 
lA Steroids PUVAJUVB PT Injection 
DMARD Systemics Biologics Biologics 
(MTX, CsA, (MTX,CsA,etc) (anti-TN F) (anti-TNF) 
SSZ, LEF) Biologics .. 
Biologics (anti-TNF, etc) 
(anti-TN F) 
Reassess Response to Therapy 
and Toxicity 
DMARD: Disease-modifying antirheumatic drug 
MTX: Methotrexate 
CsA: Cyclosporin A 
SSZ: Sulfasalazine 
LEF: Leflunomide 
PUV AIUVB: Psoralen plus ultraviolet light A orB 
Axial disease: Axial arthritis involving sacroiliac joint, spine or both 
PT: Physical therapy 
Adapted from Kavanaugh and Ritchlin 2006. 
( Enthesitis I 
Initiate 
Therapy: 
NSAID 
Injection 
Biologics 
(anti-TNF) 
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a) Traditional drugs 
Methotrexate (MTX) is the standard disease-modifying antirheumatic drug (DMARD) 
used in treatment for PsA. It is an antimetabolite which inhibits cell proliferation. MTX is 
effective in ameliorating both the skin and the joint involvement, has a rapid mode of 
action and a good safety profile (Cassell and Kavanaugh 2005; Turkiewicz and Moreland 
2007). Because MTX exhibits liver toxicity it is necessary to monitor liver and renal 
function during MTX treatment. If monitored every 6-8 weeks the risk of serious side 
effects can be avoided by stopping the drug when indicated (Hochberg 2003). 
Other DMARDs used are sulfasalazine, cyclosporin A and leflunomide (see Table 1.2). 
Sulfasalazine is a sulfa drug which is effective for the treatment of peripheral arthritis in 
PsA by acting as an anti-inflammatory agent (Turkiewicz and Moreland 2007). 
Cyclosporin A, an immunosuppressive drug that blocks T cell proliferation, has renal 
toxicity and can cause hypertension therefore it is less commonly used or only in 
combination with other DMARDs (Hochberg 2003; Turkiewicz and Moreland 2007). 
Leflunomide inhibits the de novo synthesis of pyrimidines, which T cells need to 
proliferate, thus it hinders T cell activation and proliferation (Gladman 2005). As T cells 
play a role in PsA disease pathogenesis leflunomide seems effective in treatment of PsA. 
However, its disease modifying ability remains to be determined (Gladman 2005). 
b) Biological response modifiers 
With a greater understanding of disease pathology and the need for improved treatments, 
novel therapeutic options are being explored. Biological response modifiers are now used 
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for treatment of PsA after being proven effective in other autoimmune diseases such as 
RA. The most experience so far has been obtained with TNF-a inhibitors (Cassell and 
Kavanaugh 2005). Since the start of biologic drug development in the 1990s there are 
three TNF-a inhibitors currently available: etanercept (brand name Enbrel), infliximab 
(brand name Remicade) and adalimumab (brand name Humira) (Turkiewicz and 
Moreland 2007). They all exhibit their inactivating function by binding to TNF. 
Etanercept. Etanercept is a recombinant human soluble TNF receptor. It is a fusion 
protein consisting of the extracellular portion of the human p75 TNF receptor linked to 
the Fe portion of human lgG 1 (Gladman 2005). The US Food and Drug Administration 
(FDA) approved etanercept for the treatment of PsA in 2002. In a phase II and a phase III 
clinical trial, etanercept showed sustained efficacy in improving joint and skin disease 
and this was independent of background MTX treatment (this was also seen for other 
TNF inhibitors) (Turkiewicz and Moreland 2007). Thus etanercept enables patients who 
have longstanding disease and are on a DMARD regimen to decrease or discontinue their 
concomitant treatment. Etanercept also reduced progressive joint damage as assessed by 
radiographs (Cassell and Kavanaugh 2005). Etanercept has a good safety profile and very 
good tolerability with the most common side effect being adverse reactions at the 
injection site (Gladman 2005). 
Infliximab. Infliximab is a chimeric monoclonal antibody that binds specifically to 
soluble and membrane-bound TNF-a. It consists of human constant regions and murine 
variable regions (Gladman 2005; Turkiewicz and Moreland 2007). Infliximab was 
assessed in several trials and showed good efficacy for improvement of joint 
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inflammation and skin disease (Cassell and Kavanaugh 2005; Gladman 2005; Turkiewicz 
and Moreland 2007). 
Adalimumab. Adalimumab IS a humanized anti-TNF-a monoclonal antibody. It is 
effective for treatment of both skin and joint manifestations and it also inhibits 
radiographic disease progression (Cassell and Kavanaugh 2005; Turkiewicz and 
Moreland 2007). Improvement in the quality of life for the adalimumab users was seen 
during the clinicals trials as well (Turkiewicz and Moreland 2007). The safety profile of 
adalimumab was consistent with previous results from RA trials (Gladman 2005; 
Turkiewicz and Moreland 2007). Since adalimumab is a humanized antibody the 
development of anti-chimeric antibodies by the patients is less likely (Gladman 2005). 
Despite the success with TNF-a inhibitors, about 20% of PsA patients are refractory to 
the treatment (Cassell and Kavanaugh 2005). 
1.2 CHEMOKINES AND THEIR RECEPTORS 
Chemokines, their receptors and their biological functions have been extensively 
reviewed (Luster 1998; Moser and Loetscher 2001; Le, Zhou et al. 2004; Esche, Stellato 
et al. 2005; Stein and Nombela-Arrieta 2005). In PsA, inflan1matory chemokines have 
been detected in the inflamed synovium and synovial fluid and seem to help the 
recruitment ofT cells to the site. The role of chemokines and their receptors in PsA is 
described in more detail in the Introduction of Chapter 3 (seep. 55). 
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1.2.1 Chemokine structure 
Chemokines are small ( 6-14 kD) basic proteins that share 20 to 70 percent homology in 
their amino acid sequence. The superfamily of chemokines consists of more than 50 
chemokines and has been subclassified on the basis of the position of their cysteine 
residues at the N-terminus. As shown in Table 1.3 there are four chemokine families, 
designated as C, CC (formerly P-chemokines), CXC (formerly a-chemokines) and CX3C, 
with C representing the number of cysteine residues at theN-terminus and X denoting the 
number of amino acids in between the first two cysteines (Luster 1998; Le, Zhou et al. 
2004). The biggest family features the CC chemokines with 28 members (CCL1-CCL28) 
followed by the CXC chemokines with 16 members (CXCL1-CXCL16). The C 
chemokines and CX3C chemokines are the smallest families with only two or one 
member respectively. The CXC family of chemokines is further subdivided into those 
that have a glutamic acid-leucine-arginine (ELR+) motif before the CXC sequence and 
those that do not (ELR-) (Luster 1998; Le, Zhou et al. 2004). Generally, different 
chemokine families act on different leukocytes. In this way, ELR+ CXC chemokines 
generally attract neutrophils (for example CXCL8, formerly IL-8) whereas ELR- CXC 
chemokines act on lymphocytes (for example CXCL12, formerly SDF-1 ). The CC 
chemokines attract monocytes, eosinophils, basophils and lymphocytes (Luster 1998). C 
chemokines attract T cells while CX3C chemokine (fractalkine) is chemotactic for 
T cells, natural killer cells and monocytes. Based on their function, chemokines can be 
divided into homeostatic or constitutively expressed chemokines and inflammatory or 
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inducible chemokines. Homeostatic chemokines are involved in leukocyte development 
and trafficking and help maintain the structure and organization of lymphoid organs. 
Inflammatory chemokines are induced by proinflammatory signals and are important for 
both innate and adaptive immune responses, as they are able to activate and recruit 
effector leukocytes to sites of inflammation (Le, Zhou et a!. 2004; Esche, Stellato et a!. 
2005). 
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Table 1.3: Chemokine families. 
Chcmokincs - El.R- 11/1 
CC chcmokinc~ 
CCL I 
ccu 
CCI.J 
CCL·I 
CCLS 
C:CL6 
CCL7 
CCL& 
CCL? 
CCLIO 
CCL I I 
CCLil 
CCI. IJ 
CCI.I4 
CCLIS 
CCI.I6 
CCLI7 
CCLI8 
CCI.I9 
CCL20 
CCUI 
CCI.12 
CC'I.23 
CCU.l 
ccus 
CCU6 
CCL27 
CCL28 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
CXC chernokines 
CXCL I EI.R f. 
CXCL2 El.R t 
cxcu ELR+ 
CXCI..I ELR-
C:XCI.S ELR • 
C:XCL6 ELR • 
CXCL7 El.R t 
CXCLS ELR·> 
CXCL9 ELR-
CXCLIO ELR-
CXCL II El.R-
C:XCL. 12 ELR-
CXCLIJ ELR-
C XCL14 ELR-
CXCL IS ELR-
CXCLI 6 ELR-
C chcmokiucs 
XCLI NA 
XCL2 NA 
CXJC c hcmokinc 
CXJCL I NA 
II 
II? 
II 
II 
II 
II 
II 
I 
II 
II 
II 
II 
I 
II 
Synonyms 
1-.;0?, TCAJ, 1'500 
MCP-1. MC!\F (mouse; JE) 
l.D18u, L078f\, MIP- Ia 
Acl-2. C0-26, IIC21 , 11400, Mil'· If\. LAG- I. 
SISy. MAD-5 
RANTES 
CIO (mouse). MRP- 1 (mnuse) 
MCP-3 
MCP-2, IIC 14 
M RP-2 (mouse), MIP- Iy (mouse) 
CCF I& 
cot<lxin 
MCP-5 (mouse) 
MCP-4. NCC- 1, CKf\ 10 
IICC- I. IICC-.1 , NCC-2, CKf\1 , MCIF 
IICC-2. NCC-J. MIP-S, Lkn- 1, MIP- 1 
NCC-1. LEC.IICC-4, LMC, LCC- I.CKI\12 
TARC 
DC-CKI , PA RC. Mll'~l. CKf\7. DCCK I 
ELC, MIP-Jf\. exodus-). CK[\1 1 
Mil'-.\, LARC, e'-odll>- 1. STJS, CKf\4 
SI.C, 6Ckinc. cxodus-2. TCA4. CK[\9 
MDC, STCP-1 . IX:IJ)-CK 
MIP-J. MPIF-1 , CKI\8 
MPIF-1, CKf\6. eOIII.,in-2 
TI:CK,C:K IS 
M :tjnr lt.lf£CI cells siHl \\· in g. chemotaxis 
1nonocy1cs, T cells 
monocyrcs, T cells. hasophils, NK cells. progenitors 
monocylc:i, T ccJJs, NK cells. basophils. ~osinnph il.s. 
dendritic cdl5, hcmnropoietic progenitors 
n'lc'lnocy h!S, T cell:{, dendritic cells, NK cell.;,, 
rrogcnitors 
T cell:;, cosinol)llils, hasophils, NK cells, dcndriti .. ~ cells 
n1ncrophagcs 
rnonocyrcs, T cells. cos inophils. bnsophils . NK cells. 
dendritic cells 
monocyrcs, T cells, .:os_inophils. ba~ph 1l s, NK cells 
T cel ls 
Tcclls 
co!'inophils. T ~dis 
monncytc$., T cells, cosinophils 
monncytcs., T cells.. cosinophils 
molh'k;ytcs, hcmmt>J>l) ictic progenitors 
monocyrcs, T ce-l ls, co"inophils 
T cells. ncuti'OI)hils 
Tcells 
n:.tl\·c T cdls 
T cells, ll cells , Jendritic cells, acti\:ntc:d NK cell. 
T cells. n cells 
T cells, 0 cells, dcndriric cells, ~cr ivu1cd NK cells, 
macrnpl10ge progcnito~ 
T ccii!O, cosiuophils 
dcm.1ritic cells., ostcnclnsrs 
cffccwr Th1~.:c1Js 
memory T cc.lls, B cells, immature thymocytcs 
c(ll~xin-3, IMAC, MIP-4a . TSC- 1 cosinophils, T cells 
ALP. skinkinc , ILC, ESkinc, PESKY. CTAK CLA • T cells 
MEC. CCK I T cells 
GROct. MGSA-a, NAP-J 
(mnuselra~. KC, Mll'-2. CINC-21\l 
GROct, MIP-2<.t, IVI<iSA-f\, CINC-1u 
GR0·1. MI P-1<L, CINC-11\ 
PF4 
ENA- 78 
GCP-2 
CTAPIII. NAP-2, LA-PF•I. MOC.f'. LDGF, 
1\-TG 
IL-8 . NAP- I 
Mig 
IP- 10 
1-TAC 
SI)F-1. SDF- 1, I'BSF 
BLC, BCA- 1 
BRAK, bolckinc. MIP-2, OMAC. KS I 
hw~kine 
SR-PSOX, SEXCKINE 
lymphol~clin. SCM- I, ATi\C 
SC M-I 
fractnl ~ine. ncurotoctin 
ncurrophils. cndolhe lial cell s 
ne1Hrophlls, l.!ndothdio:t.l u:lls 
llCI&(rnphtiS 
libmbbsrs, endlllhclinl cells 
ncurrnph1IS 
nl.!utrophils 
libmbl~sls 
ncwrophils. T cells, busnphils. endn1hclial cells 
T cells, progenitors 
T cells 
Tcclls 
lllOill'K:ytcs, Jl cells~ hcn1QIO!l0icric progenitors. 
non~hematot>t">ictic cells 
n cell< 
nculmpllils. NK cell!<. 13 cells'.' 
a1rspacc nctttmphils 
dendritic cells 
ll cdls, T cl.!lls. NK cells. ncutrorhi Is 
ll cells, T cells. NK cells. ncurmrhil< 
effecrnr T cells 
H. homeostatic chemokine: J. infln.mmAhlf)' chemolc.in~ NA. not appl icable. For deftnihons of the various .S)'nonym.s. ~ Ref2 1. 
From Le, Zhou, et al. 2004. 
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1.2.2 Chemokine receptor families 
Chemokines exert their function via chemokine receptors: there are eleven CC receptors 
(CCR1-11), six CXC receptors (CXCR1-6), one C receptor (XCR1) and one CX3C 
receptor (CX3CR1) as shown in Table 1.4 (Le, Zhou et al. 2004). CC receptors usually 
bind CC chemokines and CXC receptors bind CXC chemokines. There are known 
exceptions though, for example CXCL9, CXCL 1 0 and CXCL 1 1 can bind to CCR3 but 
serve as antagonists (Esche, Stellato et al. 2005). Also, there is redundancy in the 
chemokine system as some chemokine receptors can bind more than one chemokine and 
some chemokines bind to more than one receptor. The latter is true mainly for 
inflan1matory chemokines whereas homeostatic chemokines usually bind to just one 
receptor. Additionally, chemokines can bind to two decoy chemokine receptors that have 
no signaling capability: Duffy antigen receptor for chemokines (DARC) and 06 (Esche, 
Stellato et al. 2005). CC as well as CXC chemokines can bind to these decoy receptors 
but they do not induce a calcium influx (Luster 1998). 
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Table 1.4: Chemokine receptor families. 
Receptors Synonyms Chemokine lig.ands 
CCR 
CCRI CKR I, CC CKR I, CMK13R I CC!.3,5, 7 ,8,1), 14,15. 16,2.1 
CCR2 CKR~ . CC CKR2, CMKilR2 CCL2,7,8,12,13 
CCRJ CKR3, CC CKR\ Eot R, CCL5,7,8,11,13,14,15,2,1,26 
CMKBR3 
CCR·I CKR4 , CC CKR4, CMK13R4, CCLI7,22 
KS-5 
CCR5 CKR5, CC CKR5, ChcmR 13, CCLJ,4.5,8.11.1), I.J,20 
CMKDR:5 
CCR6 GPR-CY4, CKR-1.3, STRL22. CCI.20 
CRY -6, DCRl, CMKBR6 
CCR7 BLR-2, CMK13Ri CCLI?,21 
CCR8 TERI, CKR-LI , GPR-CY6, CCLI ,4,16 
ChcmR I, CMK13R8 
CCR9 GPR<J-6 CCL25 
CCRJO GPR2 CCL27,18 
CCRII PPRI CCL2,8, 13, I ?,2 1 ,25 
CXCR 
CXCRI IL-SRA, IL-SR-1, IL-8R CXCL2,3,5,6,7,8 
CXCR2 IL-8Rll, IL-8R-II , JL-8R CXCL 1.2J,5,6,7 ,8 
CXCR3 IPIO/MigR. GPR? CXCL9,10, 11 
CXCR4 IIUMSTSR fus in, LESTR. CXCLil 
IIM8? 
CXCR5 l3LR-1, MDRJ 5 CXCLJJ 
CXCR6 Bonzo. STRUJ. TYMSTR CXCLI6 
XCR 
XCRI GPR5 XCLJ. XCL2 
CX3CR 
CX:ICR I GPR 13, V28, CMKBRLI CX3CLI 
DufTy DARC CXCLI,7,8, CCL.I ,5 
D6 CCR9.10, JAI36J CCL2,4,5,8,1 \14, J 5 
NK cell. natural killer cell: DC, dendritic cell; PMN, polymorphonuclear ~ranulocy te. 
From Le, Zhou, et al. 2004. 
R~'Ceptor-cxpressing cells 
monocytcs. immature Des. T cells, PMNs. cosinophils, 
mcsang.ial cells, platelets 
monocytes, immaiure Des, basophils. PMNs, T cells, 
NK cells, endothelial cell. , fibroblasts 
eo,;inophib, basophils, T cells (Th2>Th I), DCs, 
platelets, mast cells 
immature DCs, basophils. T cells (Thl>Th I), platelets 
Th I cells, immature DCs, monocytes, 
NK cells, thymocytes 
immature DCs, T cells. 13 cells 
mature IXs, T cells, 13 cells 
monocytcs. B cells, T cells. thymocytcs 
T cells, thymoc) tes, DCs, macrophages 
T cells, melanocytes, dermal eudothelia, 
dermal fibroblast!>, Lang~rhans cells 
astrocytcs 
PMNs, monocytt:., astrocytcs. t:ndothclia, mast cells 
Pl-·fNs, monoC)'lCS, cosinophils, endothelia, mast cells 
T cells (Th I> Th:!), 13 cells, NK cells, mesangial cells, 
smooth muscle cells, endothelia 
hematopoietic pro~enitors, T cells. immature DCs. 
monocytcs. D cells, PMNs, platelets, astrocyte, endothelia 
T cells, B cell;;, astrocytcs 
memory T cells 
T cells 
Pti.·INs, monocytcs, NK cells. T cells, astrocytcs 
red blood cells, endothelia 
D cells 
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1.2.3 Chemokine receptor signaling 
Chemokine receptors are G-protein coupled receptors that have seven helical 
transmembrane domains that are connected by extramembranous loops (Allen, Crown et 
al. 2007). The NH2-terminus and three extracellular loops are located outside the cell 
whereas the cytoplasmic COOH-terminus and three intracellular loops face towards the 
inside of the cell (Allen, Crown et al. 2007). These intracellular loops contain conserved 
serine and threonine residues that become phosphorylated upon receptor binding (Ono, 
Nakamura et al. 2003). Associated with the receptor is a heterotrimeric G protein, which 
consists of three subunits (apy) and is responsible for receptor signaling. The Ga subunit 
interacts with the intracellular loops and is associated with the GP subunit which in turn 
interacts with the Gy subunit (Allen, Crown et al. 2007). In the inactive state of the 
receptor, the Ga subunit binds GDP and is not bound to the intracellular loops of the 
receptor (Janeway 2001). When a ligand binds to the chemokine receptor the 
conformation of the receptor changes, which allows the G-protein to bind to the 
intracellular loops and the GOP of the inactive form is replaced by GTP. Upon GTP 
binding, the G protein dissociates into the Ga subunit and the Gpy subunit. Both 
complexes activate downstream effectors that in turn activate signaling pathways that 
lead to the physiological response (Allen, Crown et al. 2007). Once the Ga subunit has 
bound to its effector, the GTPase activity of the Ga subunit is activated and the GTP is 
cleaved to GOP, which allows the subunit to reassociate with the Gpy subunit (Janeway 
2001). 
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1.2.4 Chemokine and receptor functions 
Chemokines and their receptors have a variety of functions. One major function is their 
ability to direct and attract leukocytes and that in turn is important during leukocyte 
development, homeostasis and inflammation. The main focus of the following paragraphs 
will be on lymphocytes. 
Lymphocyte development. Chemokines guide precursor cells to the right anatomical sites 
within primary lymphoid organs to ensure their proper development (Le, Zhou et al. 
2004). Studies by Ma et a!. showed that CXCR4 and its ligand CXCL12 are vital for 
B cell development (Ma, Jones et a!. 1998). This is most likely due to the fact that this 
chemokine and receptor pair is needed to retain precursor cells within the fetal liver and 
the bone marrow (Ma, Jones et al. 1999). Chemokines are also important for T cell 
development in the thymus. CCR7 and its ligand CCL21 are important for colonization of 
the thymus with prethymocytes during embryogenesis (Liu, Ueno et al. 2005). CCR7 
together with CCR9 and CXCR4 also help thymocytes to migrate to the different zones 
of the thymus during their development (Stein and Nombela-Arrieta 2005). 
Lymphocyte homing. Chemokines control lymphocyte trafficking within and into 
secondary lymphoid organs (SLO) where the lymphocytes get activated. If they do not 
get activated in the SLO they continue circulating between blood and lymph. The CCR7 
ligand CCL21 lets T cells enter secondary lymphoid organs as this chemokine can 
activate the integrin needed for the T cell to adhere to the SLO and enter via high 
endothelial venules (HEV) (Stein and Nombela-Arrieta 2005). Na"ive B cells use either 
CCR7 or CXCR4 to adhere and enter the SLO (Okada, Ngo et a!. 2002). Once in the 
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SLO, CCL 19 and CCL21 keep the T cells in the T cell area whereas CXCL 13 retains 
B cells, which constitutively express the CXCL13 receptor CXCR5, in the B cell 
follicles. After antigen contact, activated B cells are more responsive to the CCR7 ligands 
CCL21 and CCL 19 which help the activated B cells to migrate towards the T cell area to 
receive stimulatory signals from T cells (Kunkel and Butcher 2003). CXCL12 and 
CXCL13 also help activated B cells to form functioning germinal centers (Stein and 
Nombela-Arrieta 2005). Activated B cells also increase their responsiveness to the CCR6 
ligand CCL20, which helps them to localize to the region in the Peyer' s patches where 
antigen is transported in (Kunkel and Butcher 2003). Once the activated B cells are in the 
germinal centre, they downregulate their responsiveness to chemokines and undergo 
class-switching. Some of these germinal centre B cells will develop into plasma cells, 
which lose their expression of CXCR5 and CCR6. This loss of responsiveness seen in 
plasma cells most likely facilitates their exit from the SLO. On the other hand, some 
class-switched B cells will develop into memory cells in which case they regain 
responsiveness to CCR7, CXCR5, CCR6 and CXCR4 ligands (Kunkel and Butcher 
2003). 
Inflammation. Chemokines are also involved in controlling the migration of leukocytes 
into inflamed tissue. Infiltration into tissue by effector leukocytes occurs in chronic 
diseases as well as immune responses against pathogens. The release of inflammatory 
molecules at the site of inflammation results in the up-regulation of adhesion molecules 
and display of chemokines at the luminal side of activated endothelial cells. All these 
molecules act in concez1 to anest and bind leukocytes to the endothelium so they can 
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move through the endothelium and to the site of inflammation (Luster 1998). T H 1 
effector cells show preferential expression of CCR5 and CXCR3 to migrate to the site of 
inflammation where the respective chemokines are produced (Moser and Loetscher 
2001 ). CXCR3 is also expressed on plasma cells and a fraction of memory B cells but is 
absent from naive B cells and as forT cells CXCR3 helps these cells to migrate to sites of 
inflammation (Kunkel and Butcher 2003; Manz, Moser et a!. 2006). Additionally, 
expression of CCR6, which is also expressed by naive B cells but is only functional after 
B cell receptor cross-linking, might help memory B cells to migrate to sites of 
inflammation where there is increased release of CCR6 ligand CCL20 (Kunkel and 
Butcher 2003). 
Angiogenesis. Chemokines can influence angiogenesis positively or negatively. ELR+ 
CXC chemokines induce angiogenesis whereas ELR- CXC chemokines inhibit new 
vessel formation. However, there are exceptions such as CXCL 12, which despite its lack 
of the ELR motif has an angiogenic function (Le, Zhou eta!. 2004). 
1.3 8 CELLS IN RHEUMATIC AUTOIMMUNE DISEASE 
B cells contribute to rheumatic autoimmune diseases such as RA and systemic lupus 
erythematosus (SLE) by turning into autoantibody-producing plasma cells. 
Autoantibodies are responsible for at least part of the pathology seen in RA and SLE, as 
both diseases show immune complex mediated tissue injury (Lipsky 2001 ; Takemura, 
Klimiuk et a!. 2001 ). Edwards and Cambridge proposed a model for RA of autoantibody-
secreting B cells that start a cycle of ' self-perpetuation' in which the autoantibody 
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(rheumatoid factor in RA) provides a positive feedback signal to the autoreactive B cell. 
IgG rheumatoid factor can fix complement (C3d) thus co-ligating complement receptor 
CR2 and the autoreactive B cell receptor. Rheumatoid-factor producing B cells can 
present foreign antigen to non-autoreactive T cells, which in turn would provide the help 
to the autoreactive B cell (Edwards and Cambridge 2006). 
Still, a central role for CD4+ T cells and macrophages in disease pathology has been 
suggested in RA as autoantibodies do not correlate with disease activity and RA does also 
occur in individuals negative for rheumatoid factor (Takemura, Klimiuk et al. 200 I; 
Dorner 2006). However, as described in the following paragraphs, the role of B cells in 
rheumatic autoimmune diseases is more complex. 
B cells and ectopic lymphoid neogenesis. B cells are part of the immune cell infiltrate in 
the inflamed synovium in RA. B cells can just form a diffuse infiltrate or they can 
organize themselves into aggregates with T cells, but lacking follicular dendritic cells and 
germinal centers (Weyand, Seyler et al. 2005). However, in I 0 to 23% of RA cases they 
actually form fully developed germinal centers (GC), which are sites of B cell 
proliferation and maturation and usually only occur in secondary lymphoid organs after 
B cell activation. These GC also include T cells and follicular dendritic cells thus forming 
an organized structure where activated B cells can locally differentiate into antibody-
secreting plasma cells (Magalhaes, Stiehl et al. 2002). The formation of such organized 
structures of lymphoid cells is called ectopic lymphoid neogenesis and the GC are 
referred to as ectopic GC. The finding of these ectopic GC shows that B cell activation 
including somatic hypermutation can take place in the nonlymphoid tissue of the 
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synovmm m RA patients (Schroder, Greiner et al. 1996). Thus, it illustrates the 
involvement of B cells in the chronic inflammatory process of the disease and highlights 
the role of lymphoid neogenesis in the promotion of the autoimmune reaction. 
Furthermore, B cells contribute to the development of ectopic lymphoid structures by 
producing lymphotoxin a 1 ~2 (Takemura, Braun et al. 2001). TNF-family members such 
as lymphotoxin a1~2. are required for the development and formation of SLO and 
subsequently for lymphoid neogenesis (Takemura, Braun et al. 2001 ; Aloisi and Pujol-
Borrell 2006). Additionally, lymphotoxin is needed for the differentiation of follicular 
dendritic cells in SLO (Lipsky 2001 ). 
B cells as antigen-presenting cells (APC). A study by Takemura et a!. showed that T cell 
activation in rheumatoid synovitis is actually B cell-dependent (Takemura, Klimiuk et al. 
200 I). The authors concluded that these synovial B cells most likely function as APC for 
the T cells as they might be superior in capturing antigen in the inflamed synovium 
compared to other APC. This could be the case especially if antigen concentrations are 
limited (Takemura, Klimiuk et al. 2001). 
B cells have also been identified as APC in a murine model of RA, namely collagen-
induced arthritis. Using B cell-deficient mice Taneja et a!. could show that B cells 
efficiently present antigen to autoreactive T cells (Taneja, Krco et al. 2007). 
Co-stimulatory signals by B cells. Activated B cells can also provide co-stimulatory 
signals to the T cell. Upon activation of the B cell, OX40L expression is up-regulated and 
OX40L binds to OX40 expressed on the activated CD4 T cell. This interaction is enough 
to initiate Th2 differentiation of the T cell (Flynn, Toellner eta!. 1998). 
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Cytokine production by B cells. B cells are known to produce cytokines such as IL-6, 
TNF -a and IL- l 0. Furthermore, nai"ve B cells can be induced to produce 
immunoregulatory cytokines such as IL-2, IFN-y, IL-12 and IL-4 upon stimulation with 
antigen and polarized effector T cells thus turning into 'effector' B cells (Harris, Haynes 
et al. 2000). These 'effector' B cells can regulate nai"ve T cell development into effector 
T cells (Th I or T 112) while acting as an APC. Also, activated B cells secrete cytokines, 
which can influence the function of dendritic cells as APC (Lipsky 2001 ). 
1.3.1 BAFF in B cell autoimmunity 
The B cell activating factor BAFF (also referred to as BLyS, THANK, TALL-1 , 
TNFSF13b and zTNF4) is important for B cell activation and survival. It belongs to the 
TNF superfamily and is expressed by monocytes, macrophages, dendritic cells, 
neutrophils, stromal cells and activated T cells (Ramanujam and Davidson 2004; Seyler, 
Park et al. 2005). BAFF is a type II transmembrane protein but it can be cleaved from the 
cell membrane and thus become soluble, either in a homotrimeric or heterotrimeric form 
(Mackay, Schneider et al. 2003). BAFF binds to three different receptors, BAFF-R 
(BAFF-receptor), BCMA (B cell matw·ation antigen) and TACI (transmembrane 
activator and calcium ligand interactor). BAFF-R is expressed by mature B cells and 
memory B cells whereas BCMA is expressed highest by plasma cells. T ACI is expressed 
by mature B cells and activated T cells (Ramanujam and Davidson 2004; Seyler, Park et 
al. 2005). TACI and BCMA also bind the BAFF homologue APRIL (a proliferation-
inducing agent). APRIL signalling results in proliferation, class switching and survival of 
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B cells but it is not essential for B cell development as APRIL knock-out mice do not 
have defects in their immune system (Baker 2004; Ramanujam and Davidson 2004). 
APRIL can also form heterotrimers with BAFF but the physiological significance of 
these trimers is not fully understood (Baker 2004). 
BAFF stimulates B cell proliferation in vitro, but it acts as co-stimulatory signal only in 
combination with B cell receptor (BCR) cross-linking (Baker 2004). BAFF is important 
for B cell survival in the spleen during peripheral maturation from the T2 transitional 
stage onwards and for development of marginal zone B cells (Mackay, Schneider et a!. 
2003). Mice that do not express BAFF lack mature B cells and blocking BAFF in adult 
mice leads to the depletion of mature B cells thus showing their dependence on BAFF-
mediated survival signals (Mackay, Schneider et a!. 2003; Brink 2006). These survival 
signals are mediated via BAFF-R (Mackay, Schneider et a!. 2003). TACI on the other 
hand functions as a negative regulator of B cells and BCMA plays a role in the long-term 
survival of plasma cells. Transgenic overexpression of BAFF in mice results in a SLE-
like disorder (Gross, Johnston eta!. 2000). Also, mice of the NZWxBF1 and MRL-fpr/fpr 
mouse models of SLE show elevated levels of BAFF and the development of disease in 
the NZWxBF1 mice could be inhibited by administration of a soluble BAFF antagonist 
(Gross, Johnston et a!. 2000). BAFF antagonists have been shown to prevent arthritis in 
the DBAI mouse model of collagen-induced arthritis (Ramanujam and Davidson 2004). 
These findings in animal models suggest that BAFF levels might play a role in human 
autoimmune diseases. Elevated serum levels of BAFF have since been shown an1ong 
others in SLE patients and about 20% of RA patients show increased serum BAFF levels 
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(Cheema, Roschke et al. 2001 ). In an effort to elucidate the role of 8AFF in sustaining 8 
cell function in arthritis, Seyler et a!. showed a possible role for 8AFF and its homolog 
APRIL in the formation and maintenance of ectopic germinal centers in the inflamed 
synovium of rheumatoid arthritis patients (Seyler, Park et al. 2005). 
1.3.2 B cell depletion therapy 
As 8 cells play a number of roles in RA disease pathogenesis, 8 cell depletion therapy 
has become a new focus for RA therapy. This is especially important for patients 
unresponsive to anti-TNF treatment. The drug of choice for 8 cell depletion therapy is 
Rituximab, a chimeric anti-CD20 monoclonal antibody consisting of a human IgG 
constant region and the variable region of a murine anti-CD20 antibody (Chambers and 
Isenberg 2005). CD20 is expressed on 8 cells from the pre-8 cell stage onwards but is 
absent from plasma cells (Cope and Feldmann 2004). Rituximab depletes 8 cells mainly 
by antibody-dependent cell-mediated cytotoxicity (ADCC) but also by fixing 
complement leading to 8 cell lysis and by promoting B cell apoptosis (Edwards and 
Cambridge 2006). Rituximab was originally used for the treatment of Non-Hodgkin's 
lymphoma. Early case reports of lymphoma patients receiving Rituximab treatment 
showed a remission of coexisting RA. This led to a small exploratory study of Rituximab 
use in RA patients that were unresponsive to at least five DMARDs (Shaw, Quan et al. 
2003). With more successful trials completed, Rituximab received FDA approval for the 
treatment of RA in 2006. A small study including 20 patients showed the efficacy of 
Rituximab in a ' real life ' setting as the enrolled patients had long-standing RA and had 
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failed anti-TNF therapy. Two infusions of Rituximab were enough to sustain 
improvement for 6 months and re-treatment was only necessary at 6 to 18 months (Jois, 
Masding et al. 2007). Generally Rituximab is well tolerated with the most common 
adverse event being infusion reactions (Chambers and Isenberg 2005). Rituximab therapy 
is now also under trial in other autimmune diseases such as SLE, tmmune 
thrombocytopaenia and multiple sclerosis (Edwards and Cambridge 2006). 
B cells can also be targeted by neutralizing survival factors such as BAFF. As mentioned 
above, the inhibition of BAFF by administration of antagonists delayed disease onset in 
SLE-prone mice and inhibited collagen-induced arthritis in mice (Ran1anujam and 
Davidson 2004; Cambridge, Stohl et al. 2006). Furthermore, elevated serum BAFF levels 
have been found in patients with SLE and RA (Cambridge, Stohl et al. 2006). Thus, 
BAFF inhibition has been studied in SLE and RA patients using a monoclonal antibody 
against BAFF called Belimumab (Edwards and Cambridge 2006; Isenberg 2006). 
Belimumab produced a decrease in autoantibody levels as well as moderate B cell 
depletion in RA patients; in SLE patients there was a 12% to 4 7% reduction in B cells 
(Edwards and Cambridge 2006; Isenberg 2006). Belimumab does not seem to be as 
clinically effective as Rituximab, but animal studies indicate that Belimumab might act 
synergistically with anti-CD20 agents (Edwards and Cambridge 2006; Isenberg 2006). 
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1.4 RATIONALE AND OBJECTIVES 
The role of B cells in rheumatic autoimmune disease has been studied primarily in RA 
and its animal models, as described in section I .3. In addition to producing 
autoantibodies B cells can function as APC, cytokine producers and providers of co-
stimulation. With the successful use of B cell depletion therapy in RA, the interest has 
shifted to B cells as contributors to disease pathology. Although RA and PsA are distinct 
clinical conditions, each having unique characteristics, they share features such as 
polyarticular joint involvement and similar histology of the inflamed joint. Thus the 
evidence for the involvement of B cells in RA pathology serves as a possible indicator of 
mechanisms that may also occur in PsA. 
Research in PsA immunology has so far been focused on T cells due to several reasons. 
Firstly, the majority of PsA patients are considered seronegative for autoantibodies like 
rheumatoid factor and anti-cyclic-citrullinated-peptide antibodies (Cassell and 
Kavanaugh 2005). Also, as described in section 1.1.3 b), psoriasis is considered to be a 
T -cell-mediated disease. Consistent with the association of PsA primarily with 
HLA class I genes, CD8+ T cells are the most abundant lymphocytes found in the 
synovial fluid and in the epidermis from PsA patients. 
There is evidence for B cell involvement in PsA. A study by Veale et al. showed that 
B cells and plasma cells were present in skin biopsies taken from PsA patients with 
psoriasis but not in samples taken from psoriasis patients with no arthritis and healthy 
controls (Veale, Barnes eta!. 1994). The presence of B cells in the inflamed synovium 
was also shown by Gerhard et al. (Gerhard, Krenn et a!. 2002). Their IgVH analysis of 
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B cells from the inflamed synovium demonstrated that the B cells are actually antigen-
activated. The infiltrating B cells formed aggregates in a follicle-like pattern but follicular 
dendritic cells were absent thus indicating that there was no germinal center reaction 
present. Still, a few lgVH genes showed a clonal relationship and somatic hypermutation, 
which is indicative of a local germinal center reaction. The authors concluded that these 
clonally related IgVH genes might be the remainders of a previously present germinal 
center as germinal centers can be transient. 
Canete et a!. further studied the role of B cells in PsA and showed the presence of ectopic 
lymphoid neogenesis in PsA synovium (Canete, Santiago et al. 2007). Several studies 
have previously found lymphoid neogenesis and ectopic germinal centers in RA (see 
section 1.3). 60% of tested PsA synovial tissues had large lymphoid aggregates with 
T and B cell segregation. The authors also investigated the presence of other features 
typically present in SLO. They found vessels with high endothelial venule (HEY) 
morphology and showed that the SLO typical chemokines CXCL 13 and CCL21 were 
expressed as well, however only in the tissues containing large aggregates. Unfortunately, 
the presence of follicular dendritic cells was not studied. 
About one third of PsA patients do not respond to the treatment with TNF-a. inhibitors 
(Cassell and Kavanaugh 2005) and thus there is a need for new therapeutic options. As 
there is little known about the role of B cells in PsA pathology, apart from the studies 
mentioned above, the aim of the present study was to provide supporting evidence of 
B cell involvement in PsA. This was done in two parts, the first focusing on the migration 
of peripheral blood B cells. Since chemokines are vital for lymphocyte migration, we 
38 
hypothesized that there may be a differential expression of chemokine receptors on 
peripheral blood B cells that would allow B cells from patients with inflammatory 
arthritis to be recruited to the inflamed tissues. To test this hypothesis the expression of 
seven chemokine receptors was determined on peripheral blood B cells from PsA and RA 
patients as well as healthy controls using flow cytometry and RT-PCR and compared 
between each group. The second part of the study focused on determining B cell 
surviving factor BAFF levels in plasma, which has not been previously reported for PsA 
patients. Serum BAFF levels are known to be elevated in patients with rheumatic 
autoimmune disorders such as RA and SLE and are thought to contribute to the survival 
of autoreactive B cells in these diseases (Cheema, Roschke et al. 2001 ; Lesley, Xu et al. 
2004). If similarly elevated BAFF levels occur in PsA patients, this would add further 
weight to support the role for B cells in PsA disease pathology. This hypothesis was 
tested by analyzing the plasma BAFF levels by ELISA in PsA and RA patients and 
comparing these to BAFF levels in healthy controls. 
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CHAPTER 2 
MATERIALS AND METHODS 
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2.1 MATERIALS 
2.1.1 Chemicals 
Reagents used for agarose gel electrophoresis were purchased from Invitrogen 
(Burlington, Canada) and GE Healthcare (Baie d 'Urfe, Canada). Cell culture reagents 
like fetal bovine serum (FBS) and antibiotics were obtained from Invitrogen (Burlington, 
Canada) and Sigma Aldrich (Oakville, Canada). 
2.1.2 Molecular biology reagents 
All reagents for RT-PCR including RNA isolation, eDNA synthesis and PCR were 
purchased from Invitrogen (Burlington, Canada). Chloroform and other chemicals were 
obtained from Sigma Aldrich (Oakville, Canada). PCR primers were either purchased 
from R&D Systems (Minneapolis, USA) for the chemokine receptor assays or Integrated 
DNA Technologies (Coralville, USA) for the B-actin, CXCR3 and CD3 assays. 
Dr. Thomas Michalak kindly provided the plasmid used as positive control for the B-actin 
assay. The plasmids for the CXCR3 and CD3 assays were produced and provided by 
Shashi Gujar (Memorial University ofNewfoundland). 
2.1.3 Antibodies for flow cytometry 
All antibodies against human chemokine receptors were purchased from R&D Systems 
(Minneapolis, USA). The antibody against CD 19 (clone HIB19) was obtained from 
Biolegend (San Diego, USA). 
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2.1.4 Reagents for ELISA 
For the sandwich ELISA a Quantikine human BAFF kit (Catalogue # DBLYSO) was 
purchased from R&D Systems (Minneapolis, USA). It contained all necessary reagents 
for the ELISA including pre-coated plates, human BAFF standard and horseradish 
peroxidase conjugate. 
2.2 METHODS 
2.2.1 Sample collection 
Participants for the study were recruited at the Rheumatology clinic at Eastern Health in 
St. John's, Canada, after the study was approved by the Human Investigations 
Committee. All volunteers gave written consent to participate in the study. Patients with 
rheumatoid arthritis (RA) fulfilled the American College of Rheumatology criteria for 
RA.(Amett, Edworthy et al. 1988) Psoriatic arthritis (PsA) patients fulfilled the Moll and 
Wright criteria as patients were recruited before August 2006 when the new CASPAR 
criteria were published (Moll and Wright 1973; Taylor, Gladman et al. 2006). The 
controls were ethnically matched, unrelated to the participating patients and had no 
autoimmune disease at the time of recruitment. 
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2.2.2 Isolation of peripheral blood mononuclear cells 
For each sample, 40 mL of venous blood were collected in EDT A vacutainer tubes and 
processed within 2-3 hours of collection using Ficoll-Paque Plus (GE Healthcare, 
Baie d'Urfe, Canada). The following protocol was modified from the manufacturer's 
instructions. First, the blood was centrifuged at 400 g for 1 0-15 minutes at room 
temperature (23° C) to separate the fractions of the blood. Then the plasma layer was 
removed and stored at -80° C. The remaining blood sample was diluted with an equal 
amount of sterile PBS and slowly layered on top of Ficoll-Paque Plus (GE Healthcare, 
Baie d'Urfe, Canada) using Ficoll at 3.i.l the volume of the diluted sample. The sample was 
then centrifuged for 30-40 minutes at 400 g. The plasma phase was removed and also 
stored at -80° C. The buffy coat containing the peripheral blood mononuclear cells 
(PBMC) was transferred to a new tube and washed by adding three times the PBMC 
volume of sterile PBS. The Ficoll layer and the layer containing red blood cells and 
granulocytes were discarded. The diluted PBMC were centrifuged at 100 g for 
1 0 minutes to pellet the cells. The cells were washed by removing the supernatant and 
resuspending the cells in 10 mL PBS containing 1% FBS. The cells were then centrifuged 
for 5 minutes at 100 g. Depending on the pellet size, the cells were resuspended in 1 0-12 
mL PBS containing 1% FBS and counted using a hemacytometer (improved Neubauer 
cell). For the count the cells were diluted 1 :2 with Trypan blue to exclude dead cells. 
Viability ranged between 84 - 99%. The cells were pelleted by centrifugation for 
5 minutes at 100 g and resuspended in cooled freezing medium (RPMI 1640 containing 
10% FBS and 10% DMSO). The PBMC were a1iquoted and slowly frozen over night at 
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-80° C using a freezing container to ensure a -1 ° C/minute cooling rate. The sample 
aliquots were then transferred into a liquid nitrogen tank for long-term storage. 
2.2.3 RT -PCR 
a) B cell isolation 
CD 19+ cells (B cells) were isolated from the whole PBMC population using the magnetic 
cell separation system EasySep (Stemcell Technologies, Vancouver, Canada). The 
protocol provided by the manufacturer was followed for the EasySep separation. 
Depending on the total number of isolated PBMC, 20 x 106 - 50 x 106 total cells per 
sample were used for the magnetic cell separation. A modified version of the thawing 
protocol published by Hansen et al. was used (Hansen, Reiter et a!. 2005). First, the 
frozen PBMC were thawed in a 37° C water bath and an equal amount of chilled thawing 
medium (RPMI 1640 containing 20% FBS, 1% glutamine and 2% penicillin and 
streptomycin) was added to the thawed sample. Then the cells were centrifuged for 5 
minutes at 100 g and resuspended in 2-3 mL of warm thawing medium and incubated for 
15 minutes at room temperature (23° C). Cell viability was again determined using 
Trypan blue and the cells were counted in an improved Neubauer hemacytometer. Cell 
viability ranged between 80 - 97%. The cells were pelleted for 5 minutes at 100 g and 
resuspended in 100 ~L EasySep medium (PBS containing 2% FBS and 1 mM EDT A) 
before being transferred to a 12 x 75 mm polystyrene tube. EasySep Positive Selection 
Cocktail containing monoclonal antibodies against CD19 was added at I 00 ~LimL cells 
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( 1 0 11L for 1 00 11L cells) and the mixture was incubated for 15 minutes at room 
temperature (23° C). Then EasySep Magnetic Nanoparticles were added at 50 11LimL 
cells (5 11L for 100 11L cells) and incubated at room temperature for 10 minutes. Then the 
appropriate amount of EasySep medium was added to bring the cell suspension to a total 
volume of 2.5 mL. The suspension was mixed by pipetting and put in the magnet for 
5 minutes. Next, the supernatant fraction was poured off with the tube still in the magnet 
to keep the magnetically labeled cells in the tube. The positively selected B cells in the 
tube were then washed 3 times by adding 2.5 mL EasySep medium to the tube and left in 
the magnet for 5 minutes each time. The supernatant fractions (containing T cells, 
macrophages and NK cells) from each step were collected and pooled. The CD19- cells 
were counted using an improved Neubauer hematocytometer and centrifuged for 
10 minutes at 1 00 g before being resuspended in freezing medium (RPMI 1640 
containing 10% FBS and 10% DMSO). The cells were aliquoted and frozen as described 
above. The positively selected B cells were counted and then used for subsequent RNA 
isolation. 
To assess the purity of the positively selected fraction, CD19-PE (Biolegend, San Diego, 
USA) antibody was added at a concentration of 0.15 11g/mL immediately after adding the 
EasySep Positive Selection Cocktail. The following separation of the CD 19+ cells was 
performed as described above. Then the positively selected cells were analyzed using a 
flow cytometer (see 2.2.4 b). 94% of the positively selected cells were indeed CD 19+ B 
cells (1 0,000 total events). In another purity assessment the CD 19+ fraction was stained 
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using CD20-FITC (Biolegend, San Diego, USA) as described in section 2.2.4 a. Here 
97% of the enriched fraction was CD20 positive. 
b) RNA isolation 
The protocol for RNA isolation using TRizol (by Invitrogen, Burlington, Canada) was 
adapted from Pham et al. (Pham, MacParland et al. 2004) The separated B cells were 
lysed in 1000 ).!L TRizol and incubated for 30-60 minutes at room temperature (23° C). 
For the extraction of RNA, 200 ).!L chloroform were added and the sample was shaken 
for 15 seconds followed by a 2-3 minute incubation period at room temperature (23° C). 
Then the san1p1e was centrifuged at 12,000 g for 15 minutes at 4° C. The upper aqueous 
phase containing the RNA was transferred into a new tube containing 500 ).!L chilled 
isopropanol. RNA was precipitated overnight at -20° C using 2 ).!L of glycoblue solution 
(15 ).!gl ).!L) as co-precipitation material. Next, the RNA was pelleted by centrifugation at 
12,000 g for 10 minutes at 4° C. The RNA pellet was then washed using chilled 1000 ).!L 
75% ethanol and centrifuged at 7,500 g for 5 minutes at 4° C. The supernatant was 
removed and the RNA pellet was air-dried for about 10 minutes. After resuspension in 
10 ).!L RNase-free water the RNA was left on ice for 30 minutes. Then the RNA pellet 
was heated for 10 minutes at 55° C to completely dissolve the pellet. The RNA 
concentration was determined spectrophotometrically at a wavelength of 260 nm 
(Warburg-Christian method). The RNA was stored at -80° C before being used for eDNA 
synthesis. 
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c) eDNA synthesis 
For the eDNA synthesis, 7 IlL of total RNA (varying between 0.40 !lg - 1.69 !lg) were 
used for a 20 IlL reaction volume; a tube containing all the reagents except an RNA 
template served as a negative control. All reagents were purchased from Invitrogen 
(Burlington, Canada) and the manufacturer's protocol was followed. 125 ng random 
primers and 1 IlL of a 10 mM dNTP mix were added and the reaction heated at 65° C for 
5 minutes. After being shortly chilled on ice, 4 IlL of 5x first-strand buffer (250 mM 
Tris-HCI pH 8.3, 375 mM KCl, 15 mM MgC12) , 2 IlL of 0.1 M DTT and 40 units of 
RNaseOUT Recombinant Ribonuclease Inhibitor were added to the mixture. The reaction 
was then incubated at 3 7° C for 2 minutes. 200 units of Moloney Murine Leukemia Virus 
Reverse Transcriptase (M-MLV RT) were used for the eDNA synthesis and the reaction 
was incubated for 10 minutes at room temperature (23° C). Next, the mixture was heated 
for 40 minutes at 3 7° C and then inactivated by heating at 70° C for 15 minutes. The 
eDNA was stored at -20° C before being used in a PCR assay. 
d) PCR for chemokine receptors 
2 IlL eDNA were used for each sample for a first amplification of the house-keeping gene 
~-actin. After the first ~-actin PCR, the eDNA volumes for each sample were adjusted 
depending on the band size from 1 - 2.5 IlL eDNA to compensate for the varying 
amounts of template RNA. The adjusted eDNA volumes were then used for a second ~­
actin PCR and subsequent assays for the chemokine receptors and CD3. The PCR 
reaction was carried out following the protocol supplied by R&D Systems. 
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For a 50 f.lL PCR reaction volume, 5 f.lL of PCR buffer (containing 200 mM Tris-HCl at 
pH 8.4 and 500 mM KCl), 1 f.lL 10 mM dNTP mix, 1.5 f.lL 50 mM MgCh, 1 f.lL of each 
~-actin primer at 10 f..LM and 2.5 units of Taq DNA polymerase were added to the eDNA. 
A tube containing water instead of eDNA served as negative control for the reaction, a 
~-actin plasmid (provided by Dr. Thomas Michalak) as a positive control. The ~-actin 
primers were 5' -CAA CCG TGA GAA GAT GAC C-3' forward and 5'-ATC TCC TGC 
TCG AAG TCC - 3' reverse (kindly provided by Dr. Thomas Michalak). Next, the 
reaction was heated in a thermal cycler first for 5 minutes at 94° C followed by 35 cycles 
of 94° C denaturing for 45 seconds, 55° C annealing for 45 seconds and 72° C extension 
for 45 seconds and lastly 10 minutes at 72° C. 
The PCR products were visualized using agarose gel electrophoresis. The ~-actin product 
had a size of 339 bp and was run on a 1.5% agarose gel. Ethidium bromide solution was 
added to a final concentration of 0.5 f.lg/mL to the agarose mixture before pouring the gel. 
10 f.lL of PCR product were mixed with 2.5 f.lL BlueJuice loading buffer (Invitrogen, 
Burlington, Canada) and loaded on the gel. The gel was run in a mini-sub cell GT 
electrophoresis cell (Biorad) for about 1 hour at 80 V. The bands were then visualized 
under UV light and analyzed using the Kodak Molecular Image software. The band net 
intensity was determined and the band intensities of the chemokine receptors and CD3 
were normalized against the corresponding band intensities of ~-actin. 
The san1e procedure was followed for the PCR reactions of all the chemokine receptors. 
The primers for the receptors CXCR4 (cat. # RDP-261-025), CXCR5 (cat. # RDP-243-
025), CCRI (cat.# RDP-206-025), CCR2 (cat.# RDP-207-025), CCR5 (cat.# RDP-213-
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025) and CCR6 (cat. # RDP-237-025) were obtained from R&D Systems (Minneapolis, 
USA), which also included a positive control for each primer supplied. The primers were 
used at a concentration of 7.5 f..J.M each in the PCR reaction. The primers for CXCR3 
were 5'- CCA CCC ACT GCC AAT ACA AC - 3' forward and 5'- CGG AAC TTG 
ACC CCT ACA AA - 3' reverse as previously described by Huber el a/. (Huber, 
Reinhardt et al. 2002) and purchased from Integrated DNA Technologies (IDT, 
Coralville, USA). The CXCR3 primers were used in the PCR reaction at a concentration 
of I 0 f..J.M each. As described by Huber eta!. , the annealing temperature for these primers 
was increased to 60° C and only 30 cycles were run. The primers for the CD3 assay were 
5 ' - TGA GGG CAA GAG TGT GTG AG - 3' forward and 5' - GAG GCA GTG TTC 
TCC AGA GG - 3' reverse and also used at 1 0 f..J.M each primer. The primers were 
designed with the Primer3 program (http://frodo.wi .mit.edu/) using a human CD3£ 
mRNA sequence (accession number NM_000733). The expected CD3 product was used 
in a BLAT search (http://genome.ucsc.edu/cgi-bin/hgBlat) to test for potential genomic 
DNA products. No genomic DNA products with the same size as the eDNA product 
should be observed. The plasmids used as positive controls for CXCR3 and CD3 were 
produced and provided by Sashi Gujar. Table 2.1 lists the eDNA product sizes for the 
PCR assays analyzed. 
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Table 2.1: eDNA product sizes for analyzed PCR assays 
PCR eDNA product Genomic DNA product Positive control product 
assay SIZe SIZe SIZe 
CCRl 201 bp - 320 bp 
CCR2 406 bp - 320 bp 
CCRS 459 bp 2363 bp 320 bp 
CCR6 482 bp 579 bp 350 bp 
CXCR3 602 bp 602 bp 330 bp 
CXCR4 724 bp - 330 bp 
CXCRS 253 bp - 350 bp 
CXCR3 379 bp - 379 bp 
CD3 305 bp - 305 bp 
~-actin 339 bp - 339 bp 
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2.2.4 Flow cytometry 
a) Staining for flow cytometry 
All antibodies against the chemokine receptors (CXCR3, CXCR4, CXCR5, CCRI , 
CCR2, CCR5 and CCR6) as well as the matching mouse IgG2b and IgG I isotype 
controls were PE-conjugated and purchased from R&D Systems (Minneapolis, USA). 
The antibody against CD I9 and the matching mouse IgG 1 isotype control were 
a llophycocyanin (APC)-conjugated and obtained from Biolegend (San Diego, USA). The 
procedure was adapted from R&D Systems. For the flow cytometry staining 5 x I 06 -
I 0 x 106 PBMC were thawed as described under B cell isolation. After counting the cells 
and the last centrifugation step the PBMC were resuspended in the appropriate amount of 
PBS containing 1% FBS to get a final concentration of 5x 106 cells/mL. For each sample, 
400,000 cells was double-stained for each chemokine receptor and CD I9. The antibodies 
were titrated in a previous experiment to determine the optimum antibody concentrations, 
which are summarized in Table 2.2. After adding the appropriate amount of antibody to 
each tube, 80 J.lL of PBMC were added to the tube. In separate tubes the appropriate 
isotype controls were set up as negative controls (negative control I : mouse IgG 1-APC 
and IgG 1-PE; negative control 2: mouse IgG 1-APC and IgG2b-PE) and again 80 J.lL of 
PBMC were added to the tubes. Then the tubes were incubated for 30 minutes at 4 • C in 
the dark. After the incubation time the stained cells were washed with 1 mL of chilled 
PBS containing 1% FBS and centrifuged for 5 minutes at I 00 g. This washing step was 
repeated twice for a total 3 washes. 
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Table 2.2: Antibodies used for flow cytometry staining and their optimum concentrations 
Amount used 
Antibody Clone Conjugate I so type 
for staining 
CD1 9 HIB19 APC Mouse IgG1 0.25 ~g 
CXCR3 49801 PE Mouse lgG1 0.5 ~g 
CXCR4 44717 PE Mouse IgG2b 0.5 ~g 
CXCR5 51505. 111 PE Mouse IgG2b 0.33 ~g 
CCR1 53504 PE Mouse lgG2b 0.66 ~g 
CCR2 48607 PE Mouse lgG2b 1 ~g 
CCR5 CTC5 PE Mouse IgG1 0.33 ~g 
CCR6 53103 PE Mouse IgG2b 0.66 ~g 
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Following the last washing step the cells were resuspended in 150 ~L chilled PBS 
containing 1% FBS. The cells were then fixed by slowly adding 150 ~L of chilled 2% 
paraformaldehyde. The cells were analyzed within 2-7 days after fixation. 
b) Flow cytometry analysis 
The samples were analyzed usmg a F ACSCalibur flow cytometer (BD Biosciences, 
Mississauga, Canada) and CellQuest Pro software. First, a forward scatter vs. side scatter 
plot was created to identify the lymphocyte population according to size and granularity. 
This lymphocyte population was then gated and 50,000 events were collected in this gate. 
Next the chemokine receptor expression was determined for the CD 19+ population of the 
gated lymphocytes. Only CD 19high cells were included in the analysis (see Fig. 2.1 for 
example on gated population). For this expression analysis, the histogran1 of the isotype 
control was subtracted from the histogram of the chemokine receptor. The analysis of the 
subtracted histogram gave the percentage of chemokine receptor-positive cells as well as 
the mean fluorescence intensity for the expression. 
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Figure 2.1: Gating for CD 19+ cells. 
This is a representative density plot to show the gating strategy for B cells. After gating 
fo r the lymphocyte population, a second gate (R2) was used to gate for CD 19high cells. 
Only those cells were used fo r chemokine receptor expression analysis. 
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2.2.5 ELISA 
The Quantikine human BAFF kit from R&D Systems (Catalogue # DBL YSO) contained 
all the necessary reagents for the ELISA including pre-coated plates, human BAFF 
standard and horseradish peroxidase conjugate. First I 00 ~L/well of the supplied assay 
diluent were added to the plate followed by 50 ~L of undiluted plasma or standard. The 
standard curve covered a range from 0.0625 ng/mL to 4 ng/mL. The plate was then 
incubated for 2 hours at room temperature and then washed 4 times using the provided 
washing buffer. Then 200 ~L/well of HRP conjugate were added and the plate was again 
incubated for 2 hours at room temperature. After another 4 washes, 200 ~L/well of 
provided substrate solution were pipetted into each well and the plate was incubated for 
30 minutes at room temperature in the dark. The reaction was stopped using 50 ~L/well 
of 2 N sulfuric acid. As recommended in the manufacturer's instructions, the plate was 
read at 450 nm with 550 nm as reference wavelength to correct for optical imperfection 
on the plate. By linear plotting of the optical density (mean of duplicates) against the 
corresponding standard concentration, a standard curve was generated. A linear trendline 
was added which was used to calculate the concentration in the plasma samples. 
2.2.6 Statistical analysis 
All statistical analysis was performed using Graphpad Prism 4.0. To compare the 
expression levels between the three groups (healthy control, RA, PsA) for both the 
chemokine receptor expression and the BAFF ELISA a nonparametric ANOVA 
(Kruskal-Wallis test) was used to determine significant differences in expression. A 
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Dunn' s post test, which calculates a p-value for each pair of columns, was performed to 
determine which groups showed significant differences compared to the other groups. A 
p-value below 0.05 was considered significant. To test data for correlation with clinical 
parameters (BAFF ELISA data) or CD3 expression ( chemokine receptor expression data) 
the Spearman test was performed. 
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CHAPTER 3 
COMPARISON OF CHEMOKINE RECEPTOR EXPRESSION BY 
PERIPHERAL BLOOD 8 CELLS FROM PATIENTS WITH PSORIATIC 
AND RHEUMATOID ARTHRITIS 
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3.1 INTRODUCTION AND RATIONALE 
Lymphocyte trafficking throughout the body is guided by chemotactic factors such as 
chemokines, which exert their function via their respective chemokine receptors. Thus 
lymphocytes can home to different sites of the body according to the expression profile of 
adhesion molecules and chemokine receptors of various tissues (Burman, Haworth et al. 
2005). This 'area code model' enables lymphocytes to migrate to sites of inflammation 
where the corresponding chemokines are expressed to attract lymphocytes to the site. As 
described in Chapter I , B cells are part of the cellular infiltrate into the PsA synovium 
and the development of ectopic lymphoid structures in PsA has been shown. The aim of 
the work described here was to show a possible recruitment of peripheral blood B cells to 
sites of inflammation in PsA patients. We hypothesized that differential expression of 
chemokine receptors on peripheral blood B cells would allow these B cells to migrate to 
the inflamed joints. The following paragraph describes the chemokine receptors that were 
selected for expression analysis. Some of these receptors are not constitutively expressed 
by B cells but have been shown to play a role in arthritis and PsA and were therefore 
chosen for the study. Other receptors are constitutively expressed by B cells and were 
selected since they are important for B cell migration. Other constitutively expressed 
chemokine receptors such as CCR 7 were not analyzed as only a limited amount of 
receptors could be analyzed for this study. 
The inflammatory chemokine CCL5 is found m PsA synoviUm and is produced by 
infiltrating T cells (Konig, Krenn et al. 2000). CCR5, one of the receptors for CCL5, is 
expressed by infiltrating mononuclear cells in the synovial fluid in PsA and RA patients 
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(Mack, Bruhl et al. 1999), which possibly enables these cells to migrate to the inflamed 
joint where CCL5 is produced. Another receptor activated by CCL5 is CCR1. The role of 
CCR1 in arthritis has been shown using the collagen-induced arthritis mouse model 
where a CCR1 antagonist was effective in ameliorating disease severity and incidence 
(Plater-Zyberk, Hoogewerf et al. 1997). Also, a human CCR1 antagonist is in a phase II 
clinical trial for use as a treatment of rheumatoid arthritis (Charo and Ransohoff 2006). 
Another inflammatory chemokine, CXCL9, has also been detected by 
immunohistochemistry in the synovium of PsA patients and seems to work together with 
CCL5 to recruit T cells to the inflamed synovium (Konig, Krenn et al. 2000). The 
CXCL9 receptor CXCR3 has been shown to be expressed by effector T cells as well as 
plasma cells and a fraction of memory B cells, which helps these cells to migrate to sites 
of inflammation (Moser and Loetscher 2001; Kunkel and Butcher 2003; Manz, Moser et 
al. 2006). CCL2 is another inflammatory chemokine that has been found in increased 
amounts in the synovial fluid of PsA patients compared to patients with non-
inflammatory arthritis; thus, the CCL2 receptor CCR2 was investigated in this study 
(Ross, D'Cruz et al. 2000). CCR2 is also expressed by mononuclear cells in the synovial 
fluid of RA patients (Mack, Bruhl et al. 1999), thus, like other chemokine receptors, it 
might be important for these cells to travel to the inflamed joint. 
The chemokine receptors CXCR4, CXCR5 and CCR6 are receptors for homeostatic 
chemokines that are constitutively expressed by B cells. Activated B cells increase their 
responsiveness to the CCR6 ligand CCL20, which might help memory B cells to migrate 
to sites of inflammation that release increased amounts of CCL20 (Kunkel and Butcher 
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2003). Similarly, it has been shown in psoriasis that CCL20 is expressed by keratinocytes 
in lesional psoriatic skin but not in nonlesional and normal skin. Since memory T cells 
that home to the skin express high levels of CCR6, CCL20 expression might help recruit 
memory T cells to the psoriatic lesion (Homey, Dieu-Nosjean et a!. 2000). As described 
in chapter 2, CXCR4 and CXCR5 are important for B cell migration into and within 
secondary lymphoid organs. CXCR4 and CXCR5 are also required for GC organization 
(Stein and Nombela-Arrieta 2005). Additionally, T cells found in RA synovium express 
high levels of CXCR4, which could explain their retention in the synovium as synovial 
endothelial cells produce CXCL12 (Buckley, Amft et al. 2000). 
To test the hypothesis of a differential chemokine receptor expression on peripheral blood 
B cells from PsA patients, the expression of CXCR3, CXCR4, CXCR5, CCRl , CCR2, 
CCR5 and CCR6 was analyzed using RT-PCR and flow cytometry and compared to the 
expression on B cells from healthy controls and RA patients who served as disease 
controls. 
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3.2 RESULTS 
3.2.1 Patients 
The RA patients recruited for the study fulfilled the American College of Rheumatology 
criteria for RA (Arnett, Edworthy et al. 1988) and the PsA patients fulfilled the Moll and 
Wright criteria (Moll and Wright 1973). Volunteers who were ethnically matched and 
had no known autoimmune disease when they entered the study were used as controls. 
The demographics of the study participants are summarized in Table 3.1. 
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Table 3.1: Demographics and treatment of patients and volunteers enrolled for study. 
PsA patients RA patients Healthy controls 
Total number 37 24 35 
Age 
Mean (range) 49(21-72) 59 (38-79) 33 (20-54) 
Sex 
Male 17 4 13 
Female 20 20 22 
Rheumatoid factor 
(IgM) 
n.d. 16 n.d. 
Positive 
8 
Negative 
Active joint count 
Mild (5 joints and less) 28 12 
n.a. 
Moderate (6-9 joints) 5 6 
Severe (> 10 joints) 4 6 
Treatment 
None 1 
NSAIDS only 3 2 
n.a. 
DMARDs 103 13c 
Anti-TNF agents 9b 4d 
Prednisone 12 13 
3one patient additionally on anti-TNF agent, four patients additionally on prednisone 
btwo patients additionally on prednisone (but not MTX), two patients additionally on 
MTX (but not prednisone) 
ctwo patients additionally on anti-TNF agent and prednisone, six patients additionally on 
~rednisone 
two patients additionally on MTX and prednisone, one patient additionally on 
prednisone 
n.d. not determined; n.a. not applicable 
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3.2.2 Summary of results 
The RT-PCR results are summarized in Table 3.2 and the flow cytometry results are 
summarized in Table 3.3. 
As described in Materials and Methods, a non parametric AN OVA (Kruskal-Wallis test) 
was used to determine differences in chemokine receptor expression between the three 
investigated groups. This creates one p-value for comparing three groups and the 
subsequent post-test (Dunn's post-test) determines between which groups the significant 
difference lies. Thus, if there is no statistical significant difference, only one p-value is 
reported as all the p-values of the post-test are above 0.05. 
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Table 3.2: Summary ofRT-PCR results. 
Shown is the mean ratio including standard deviation (ratio is the receptor net intensity 
normalized against ~-actin band net intensity). 
RT -PCR expression by B cells 
HC RA PsA p-value* 
CXCR3 0.0568 0.0372 
0.0184 0.0598 
±0.032 so ±0.024 so ±0.005 so 
(n = 5) (n = 5) (n = 5) 
CXCR4 
1.2450 1.1 40 1.260 0.661 
±0. 174 so ±0.1 20 so ±0.303 so 
(n = 5) (n = 3) (n = 4) 
CXCRS 
0.5740 0.5750 0.3925 0.2346 
±0.1 47 so ±0.101 so ±0. 147SO 
(n = 5) (n = 4) (n = 4) 
CCRl 
0.0417 0.0640 0.0377 0.0679 
±0.034 so ±0.02 1 so ±0.025 so 
(n = 9) (n = 9) (n = 9) 
CCR2 0.1059 0.0694 
0.0392 0.3330 
±0.121 so ±0.048 so ±0.032 so 
(n = 9) (n = 9) (n = 9) 
CCRS 
0.0297 0.0359 0.0143 0.0656 
±0.03 1 so ±0.017 so ±0.012 so 
(n = 9) (n = 9) (n = 9) 
CCR6 0.2836 
0.2194 0.131 4 0.2066 
±0.229 so ±0.198 so ±0. 126 so 
(n = 9) (n = 10) (n = 12) 
*p-values refer to comparison of expression levels from all three groups 
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Table 3.3: Summary of flow cytometry results. 
Shown is the mean of percent positive B cells as well as mean fluorescence intensity. 
Percent positive B cells 
HC RA PsA p-value (n = I 0) (n = 15) (n = 13) 
CXCR3 77.47 70.34 70.83 0.2 193 
±5 .84 SD ± 11.10 SD ± 12.62 
CXCR4 90.60 90.82 91.04 0.5895 
±2.21 SD ±4.69 SD ±5.31 SD 
CXCRS 94.94 93 .89 92.03 0.3059 
±2.43 SD ±2.58 SD ±5.50 SD 
CCRl 3.84 4.84 5.50 0.3833 
± 1.03 SD ±3.61 SD ±2.62 SD 
CCR2 9.41 7.69 I 0.49 0.1643 
±7.68 SD ±5.37 SD ±5.01 SD 
CCRS 3.65 4.75 4.29 0.7864 
± 1.59 SD ±3.01 SD ±2.67 SD 
CCR6 92.34 89.52 89.69 0.2839 
±3.06 SD ±5.14SD ±8.62 SD 
Mean fluorescence intensity 
HC RA PsA p-value 
CXCR3 143.1 138.9 179.6 0.0686 
±28.64 SD ±25.84 SD ±69.13 
CXCR4 278.8 284.5 343.4 
±83.29 0.1069 
±30.80 SD ±61.17 SD SD 
CXCRS 5 11 .5 479.5 476.3 
±90.58 0.3254 
± 78.63 SD ±7 1.20 SD SD 
CCRl 
n.a. n.a. n.a. n.a. 
CCR2 
n.a. n.a. n.a. n.a. 
CCRS 
n.a. n.a. n.a. n.a. 
CCR6 242.6 2 13.2 
252.8 
± 102.9 0.4824 
± 103.3 SD ± 82. 17 SD 
n.a. = not applicable; p-values refer to companson of all three groups 
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3.2.3 CXCR3 expression 
a}RT-PCR 
The expression of CXCR3 by peripheral blood B cells was first determined at the RNA 
level using RT-PCR. CD19+ B cells were first isolated from PBMC using magnetic cell 
separation as described in Chapter 2 (Materials and methods) and then subsequently used 
for total RNA isolation, eDNA synthesis and PCR. A plasmid containing the human 
CXCR3 sequence served as positive control for the PCR. Five samples were analyzed for 
each of the investigated groups (PsA patients, RA patients and healthy controls). The 
PCR products were visualized using agarose gel electrophoresis and the net intensities of 
the CXCR3 product bands were normalized against the net intensities of the 
corresponding ~-actin product bands (CXCR3/~-actin ratio). 
As seen in Figure 3.1, isolated B cells from all groups expressed CXCR3 mRNA in low 
amounts. The PsA group showed the lowest expression with a mean ratio of 0.018 
(± 0.002 standard error of mean) compared to healthy controls (0.057 ±0.015 SEM) and 
RA patients (0.037 ±0.010 SEM). Even though there was a trend visible, there was no 
significant difference between the three groups (p-value of 0.0598). There was also a 
large variation in CXCR3 mRNA expression within the RA group and healthy control 
group. 
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b) Flow cytometry 
To see if a similar trend could be observed at the protein level, the expression of CXCR3 
protein was also analyzed using flow cytometry. PBMC from 13 PsA patients, 15 RA 
patients and ten healthy controls were stained for CD19 and CXCR3. Then the CXCR3 
expression of the gated CD 19+ population was determined by subtracting the isotype 
control histogram from the CXCR3 histogram. A density plot showing the gated 
population can be found in Chapter 2 (p. 54). The results of the chemokine receptor 
expression analysis are shown in Fig. 3 .2. The majority of B cells did express CXCR3 
and there was no significant difference (p = 0.2193) in the number of CXCR3+ B cells 
between the three groups although RA (mean 70.34% ±2.87% SEM) and PsA patients 
(mean 70.83 ±3.50 SEM) showed a trend for a decrease in CXCR3+ B cells compared to 
healthy controls (mean 77.47% ± 1.85 SEM). 
As determined by mean fluorescence intensity, despite most B cells expressing CXCR3, 
the B cells expressed it at lower levels compared to expression levels of other chemokine 
receptors such as CXCR4 and CXCR5. There was no significant difference in mean 
fluorescence intensity between the three groups (p= 0.0686) but the PsA group was the 
highest expressing group with a mean of 179.6 ±19.17 SEM compared to a mean of 
143.1 ±9.06 SEM for healthy controls and a mean of 138.9 ±6.67 SEM for RA patients. 
In viewing Figure 3.2 B there clearly appears to be an outlier. Taking the outlier out of 
the analysis did not change PsA as the highest CXCR3-expressing group although the 
mean decreased slightly (from 179.6 to 162.6). Exclusion of the outlier did not result in a 
significant expression difference (p = 0.1 252). 
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3.2.4 CXCR4 expression 
a)RT-PCR 
The expression of CXCR4 was first determined usmg RT-PCR. Five samples from 
healthy controls, three samples from RA patients and four samples from PsA patients 
were used for analysis. The net intensities of the CXCR4 product bands were normalized 
against the net intensities of the corresponding P-actin product bands. There was no 
statistically significant difference in mRNA expression between the investigated groups 
(p = 0.661) and all groups expressed CXCR4 mRNA in high amounts as shown in Fig. 
3.3. CXCR4 was the only receptor showing a stronger expression than the house-keeping 
gene P-actin with a ratio > 1 for all groups. 
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b) Flow cytometry 
The expression of CXCR4 protein was also analyzed using flow cytometry. The results 
are shown in Fig. 3.4. Samples from ten healthy controls, 13 PsA patients and 15 RA 
patients were analyzed. Almost all B cells expressed CXCR4 (91% of CD19+ B cells) 
and there was no significant difference in numbers of CXCR4+ B cells between PsA and 
RA patients and healthy controls (p = 0.5895). When compared to the expression of other 
chemokine receptors, B cells from all groups expressed higher levels of CXCR4 protein. 
There was no significant difference in mean fluorescence intensity between the three 
groups (p = 0.1 069). However, there was a trend for PsA being the highest expressing 
group with mean fluorescence intensity of 343.4 ±23. 1 SEM compared to healthy 
controls (256.8 ±9.7 SEM) and RA patients (284.5 ± 15.8 SEM). The highest variation 
was seen in the PsA group with a range in mean fluorescence intensity from 210 to 483. 
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3.2.5 CXCRS expression 
a}RT-PCR 
Five healthy controls, four RA patients and four PsA patients were used for RT-PCR 
analysis to determine CXCR5 mRNA expression. The net intensities of the CXCR5 
bands were normalized against the corresponding P-actin bands (ratio of CXCR5/P-
actin). As shown in Fig. 3.5, all groups expressed medium amounts of CXCR5 mRNA 
(ratio for healthy control and RA patients 0.574 ±0.066 SEM and 0.575 ±0.050 SEM 
respectively, ratio for PsA patients 0.393 ±0.074 SEM) with no statistically significant 
difference between the groups (p = 0.2346). The expressed amount of CXCR5 mRNA 
was moderate and similar among the majority of samples so no further samples were 
analyzed for CXCR5 mRNA expression. 
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b) Flow cytometry 
The results of CXCR5 expression analysis at the protein level are shown in Fig. 3.6. 
Samples from ten healthy controls, 13 PsA patients and 15 RA patients were analyzed. 
B cells from all three groups expressed CXCR5 (92-95% of CD 19+ B cells) and no 
statistically significant difference was seen between the three investigated groups 
(p = 0.3059). The highest variation was seen in the PsA group with a range of 80.3% to 
96.9 % B cells expressing CXCR5, which was due to two samples that appear to be 
outliers. Excluding these two samples did not result in a significant difference in 
CXCR5+ B cell numbers between the three groups (p = 0.3972). 
In comparison to the other investigated chemokine receptors, CXCR5 showed the highest 
expression level by B cells from all three groups. There was no significant difference in 
mean fluorescence intensity between the three groups (p = 0.3254) and the variance 
within each group was similar for all groups (mean fluorescence intensity for PsA 
patients 476.3 ±25.12 SEM, for RA patients 479.5 ± 18.38 SEM and healthy controls 
511.5 ±24.86 SEM). 
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3.2.6 CCR6 expression 
a}RT-PCR 
Nine healthy controls, ten RA patients and 12 PsA patients were analyzed using RT-PCR 
to determine CCR6 mRNA expression. The net intensities of the CCR6 bands were 
normalized against the corresponding P-actin bands (ratio of CCR6/P-actin). 
All groups expressed medium amounts of CCR6 mRNA (mean ratio for healthy controls 
0.284 ±0.076 SEM, mean ratio for RA patients 0.220 ±0.063 SEM and mean ratio for 
PsA patients 0.131 ±0.036 SEM) with no statistically significant difference (p = 0.2066) 
between the groups as shown in Fig. 3.7. The PsA group showed the lowest expression 
compared to the other groups. In all three groups the variance was high and ranged from 
not detectable to a ratio of 0.333 for PsA patients, not detectable to 0.514 for RA patients 
and from a ratio of 0.056 to 0. 771 for healthy controls. 
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b) Flow cytometry 
Fig. 3.8 shows the results of the flow cytometry experiment for ten healthy controls, 13 
PsA patients and 15 RA patients that were used for analysis. 
In all three groups the majority of B cells expressed CCR6 and no significant differences 
in numbers of CCR6+ B cells were seen between any of the groups (p = 0.2839). The 
highest variance was seen in the PsA group with a mean of 89.69 ±2.39 SEM compared 
to the RA group (mean 89.52 ±1.33 SEM) and healthy controls (mean 92.34 ±0.96 SEM). 
This variance in the PsA group was due to two samples that appear to be outliers. 
Excluding these two samples did not result in a significant difference in CCR6+ B cell 
numbers between the three groups (p = 0.1 063). 
In comparison to the other investigated chemokine receptors, CCR6 showed a medium 
level of expression by B cells from all groups. There was no significant difference 
(p = 0.4824) in mean fluorescence intensity between PsA patients (252.8 ±28.54 SEM), 
RA patients (213 .2 ±21.22 SEM) and healthy controls (242.6 ±32.65 SEM). All three 
groups showed similar variance, for healthy controls and the PsA group this was mainly 
due to two samples that can be seen as outliers. Again, excluding these samples from the 
analysis did not result in a significant difference in CCR6 expression between the three 
investigated groups (p = 0.7880). 
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3.2.7 CCRl expression 
a}RT-PCR 
To determine the CCR1 mRNA expression using RT-PCR, nine samples per investigated 
group were analyzed. Again the CCRl band intensities were normalized against the 
corresponding ~-actin band intensities. 
The results in Fig. 3.9 show low expression of CCR1 mRNA by PsA and RA patients as 
well as healthy controls. There was no significant difference in expression between the 
three groups (p = 0.0679) although there was a trend of RA being the highest expressing 
group with a mean ratio of 0.064 ±0.007 SEM compared to healthy controls (mean ratio 
0.042 ±0.011 SEM) and PsA patients (mean ratio 0.038 ±0.008 SEM). The healthy 
control group had the highest variation with the CCRl mRNA expression ranging from 
not detectable (ratio of 0) to a ratio of 0.1 07. Variation was also seen within the PsA 
group with two samples whose CCRI mRNA expression could not be detected. 
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b) Flow cytometry 
The results of the flow cytometry analysis for CCRl are shown in Fig. 3.1 0. As for the 
other chemokine receptors, samples from ten healthy controls, 13 PsA patients and 15 
RA patients were analyzed. The majority of CD 19+ B cells did not express measurable 
amounts ofCCRI. For those with CCR1 expression, there was no statistically significant 
difference (p = 0.3833) in CCR1 + B celL numbers between PsA patients (mean of 5.00% 
±0.73 SEM), RA patients (mean of 4.84% ±0.93 SEM) and healthy controls (mean of 
3.84% ±0.33 SEM). The highest variation in CCR1 + B cell numbers within one group 
was observed for RA patients (range from 1.62% to 14.01 %) and PsA patients (range 
from 2.22% to 10.69%). The variation in the RA patient group was due to two samples. 
Exclusion of these two samples from expression analysis did not result in a significant 
difference in CCR 1 + B cell numbers between the three groups (p = 0.1290) The amount 
of expressed CCR1 was low with no visible shift of the CCRl peak compared to the 
isotype control for any of the analyzed groups. Thus the mean fluorescence intensity was 
not compared between the groups. 
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3.2.8 CCR2 expression 
a}RT-PCR 
Nine samples per group (healthy controls, PsA patients and RA patients) were used for 
RT-PCR analysis of CCR2 mRNA expression. As with the previously analyzed 
chemokine receptors, CCR2 bands were normalized against the corresponding ~-actin 
band intensities. There was low expression of CCR2 mRNA by all groups as shown in 
Fig. 3.11. The PsA group was the lowest expressing group (0.039 ±0.011 SEM) 
compared to healthy controls (0.106 ±0.040 SEM) and RA patients (0.069 ±0.016 SEM) 
however the differences seen between the groups were not significant (p = 0.3330). The 
healthy control group showed the highest amount of variation with a range from 0.007 to 
0.314. This was mainly due to two samples within this group that seem to be outliers. 
Excluding these samples from the analysis lowered the ratio for the healthy control group 
to 0.047 ±0.014 SEM but did not change the result of the statistical analysis (p = 0.2975). 
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b) Flow cytometry 
Ten healthy controls, 13 PsA patients and 15 RA patients were analyzed for CCR2 
expression using flow cytometry as shown in Fig. 3.12. 
Only about 10% of the CD 19+ B cells actually expressed CCR2. No significant difference 
(p = 0.1643) in CCR2+ B cell numbers was seen between PsA patients (mean I 0.49% 
± 1.39 SEM), RA patients (mean 7.69% ±1.39 SEM) and healthy controls 
(mean 9.41% ±2.43 SEM). The highest variation was in the patient groups (PsA range 
3.37% - 18.09% and RA range 2.94 - 22.66%) and the variation seen for the healthy 
controls was mainly due to one sample. Excluding this sample did not result in a 
significant difference in CCR2+ B cell numbers between the three groups (p = 0.1401). 
The amount of expressed CCR2 was low with only a small shift of the CCR2 peak 
compared to the isotype control for any of the analyzed groups. Thus the mean 
fluorescence intensity was not compared between the groups. 
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3.2.9 CCRS expression 
a}RT-PCR 
As for the previous receptors, nine samples per investigated group were used for CCRS 
mRNA expression analysis. Again, CCRS band intensities were normalized against the 
corresponding P-actin band intensities. 
As shown in Fig. 3.13 all groups expressed very low amounts of CCRS mRNA. There 
were no significant differences between the three analyzed groups (p = 0.0656), but the 
PsA group seemed to be the lowest expression group (ratio 0.014 ±0.004 SEM) compared 
to healthy controls (ratio 0.030 ±0.010 SEM) and RA patients (ratio 0.036 ±0.006 SEM). 
Some variance was seen in all three groups however the highest variance was seen for the 
healthy control group with sample ratios ranging from not detectable to 0.092. Again this 
was mainly due to two samples that appeared to be outliers. Excluding these outliers from 
the statistical analysis resulted in a significant difference between RA patients and PsA 
patients (p = 0.0239) with RA patients showing a higher expression compared to PsA 
patients. 
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b) Flow cytometry 
For CCR5 expression at the protein level, ten healthy controls, 13 PsA patients and 15 
RA patients were analyzed using flow cytometry. 
The results in Fig. 3.14 show that there was no significant difference of the mean number 
of B cells expressing CCR5 between the three groups (p = 0.7864). Numbers of cells 
expressing CCR5 was low, only about 4% of CD19+ B cells expressed CCR5. For 
healthy controls it was 3.65% ±0.50 SEM, for PsA patients 4.29% ±0.74 SEM and for 
RA patients 4.75% ±0.78 SEM. The highest variation was seen in the RA group, ranging 
from 0.54% positive B cells to 10.65% positive B cells. The variation seen in the PsA 
group was mainly due to one sample that appears to be an outlier. Excluding this sample 
from the statistical analysis did not result in a significant difference in CCR5+ B cell 
numbers between the investigated groups (p = 0.6871 ). 
The amount of expressed CCR5 was low with no shift of the CCR2 peak compared to the 
isotype control for any of the analyzed groups. Thus the mean fluorescence intensity was 
not compared between the groups. 
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3.2.10 CD3 expression 
Despite the high purity of the separated B cell population (94%-97% CD20+ B cells) as 
determined by flow cytometry, expression of CD3 was analyzed using RT-PCR to 
exclude the influence of chemokine receptor-expressing T cells. The results are shown in 
Figure 3.15. All groups showed low expression of CD3 (mean ratio for healthy controls 
0.116, mean ratio for RA patients 0.0852 and mean ratio for PsA patients 0.054 7), which 
is similar to the ratio observed for low expressing chemokine receptors. This detection of 
CD3 expression was expected, as RT-PCR is sensitive enough to detect any T cells 
present in the enriched B cell population. The PsA group showed the lowest CD3 
expression of the three groups, similarly the PsA group was observed to be the lowest 
expressing group for the chemokine receptors CXCR3, CCR2, CCR5 and CCR6, which 
are also expressed by T cells. To determine if this trend to be the lowest expressing group 
was due to less CD3+ T cells present, possible correlation between the amount ofT cell 
contamination (as determined by CD3 expression) and expression levels of the 
chemokine receptors were tested using the Spearman test. The results of this analysis are 
shown in Fig. 3 .16. There were no statistically significant correlations observed between 
chemokine receptor expression and CD3 expression, but trends were visible. Healthy 
controls did show a trend for a positive correlation between CD3 expression and CXCR3 
(r = 0.90, p = 0.083). PsA patients did show a trend for a positive correlation between 
CCR2 and CD3 expression (r = 0.83, p = 0.058). RA patients showed a negative trend for 
a correlation between CD3 and CCR2 expression (r = -0.95, p = 0.083) as well as a 
negative correlation between expression ofCD3 and CCR6 (r = -0.72, p = 0.136). 
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Figure 3.15: RT-PCR results for CDJ expression. 
Scatter dot plot of band net intensities showing mean and standard error of mean m 
colour. The CDJ band net intensities were normalized against the corresponding P-actin 
band intensities (ratio = band intensity of CDJ band/band intensity of P-actin). 
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3.3 DISCUSSION 
Differential expression of chemokine receptors promoting B cell migration to sites of 
inflammation in PsA and RA patients was investigated in this part of the thesis. To test 
this hypothesis, chemokine receptor expression was first analyzed at the RNA level using 
RT-PCR. The RT-PCR results are summarized in Table 3.2 (p. 61). These results showed 
that CXCR4 was expressed more strongly than any other chemokine receptor as 
determined by CXCR4 band intensity normalized against P-actin band intensity 
(CXCR4/P-actin ratios for all investigated groups > 1 ). CXCR5 was also expressed 
strongly (ratios for all groups about 0.5). CCR6 showed a medium expression compared 
to other chemokine receptors. Lower expression levels were seen for CXCR3, CCRI , 
CCR2 and CCR5, with CCR5 showing the lowest expression. 
To determine chemokine receptor expression at the protein level as well, the same 
receptors were also analyzed using flow cytometry. Firstly, the percentage of CD 19+ B 
cells expressing the analyzed chemokine receptors was investigated. The results of that 
experiment are summarized in Table 3.3 (p. 62) and show that the majority of CDI9+ B 
cells (>90%) expressed CXCR4, CXCR5 and CCR6. This was expected as these 
chemokine receptors have been reported to be constitutively expressed by B cells (David 
2000). CXCR3 was expressed by about 75% of peripheral blood B cells whereas CCRI , 
CCR2 and CCR5 were only expressed by a fraction of B cells (< 10%). These results for 
chemokine receptor expression on peripheral blood B cells are similar to previously 
published data (Henneken, Dorner et al. 2005) that show comparable percentages in 
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expression for healthy controls. However, in another publication CXCR3 was expressed 
by only 15%-25% of peripheral blood B cells (Jones, Benjamin et al. 2000). 
The level of chemokine receptor expression was determined by measurement of mean 
fluorescence intensity and this is also summarized in Table 3.3. CXCR5 showed very 
high mean fluorescence intensity and was expressed the highest compared to the other 
chemokine receptors. CXCR4 and CCR6 also showed high expression whereas CXCR3 
showed low expression. CCR1, CCR2 and CCR5 were expressed in such low amounts 
that it did not result in a measurable peak shift from the negative control. More B cells 
(8%-11 %) expressed CCR2 than CCR1 (3%-6%) or CCR5 (3%-5%). 
The comparison of the results obtained by RT-PCR and flow cytometry showed that the 
high expression for CXCR4 and CXCR5 seen at the protein level was also observed at 
the RNA level. However, CXCR4 showed stronger mRNA expression than CXCR5, 
which is probably due to contamination with other mononuclear cells (which were not 
measured), that also express CXCR4 (David 2000). CCR6 showed lower expression than 
CXCR4 and CXCR5 at the RNA level as well as the protein level. CXCR3 showed lower 
expression when analyzed using RT-PCR and although most B cells were actually 
positive for CXCR3 they appeared to express CXCR3 at a lower level compared to 
CXCR4, CXCR5 and CCR6 (between the three investigated groups of patients and 
controls mean fluorescence intensity ranged from 138.9-179.6 for CXCR3 compared to 
278.8-343.4 for CXCR4 and 213.2-252.8 for CCR6). As seen at the protein level with 
more B cells expressing CCR2, the RT-PCR results showed that CCR2 was higher 
expressed with an average ratio of 0.071 compared to CCRI and CCR5 expression 
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(average ratio of 0.048 and 0.027 respectively). Taken together the flow cytometry data 
supported and confirmed the results obtained with RT-PCR in terms of expression levels 
(as determined by mean fluorescence intensity) and the expression pattern of the 
chemokine receptors was similar as well. 
We detected no differential expression between the three investigated groups (PsA 
patients, RA patients and healthy controls) for any of the analyzed chemokine receptors 
at the mRNA or the protein level. At the mRNA level, the PsA group showed a trend for 
being the lowest expressing group for CXCR3 and CCR5 (p = 0.0598 and p = 0.0656 
respectively) whereas the RA group showed a trend to be the highest expressing group 
for CCR 1 (p = 0.0679). At the protein level though the PsA group showed a trend to 
express higher levels of CXCR3 (p = 0.0686; mean fluorescence intensity of 179.6 
compared to 143.1 for healthy controls and 138.9 for RA patients) and CXCR4 (p = 
0.1 069; mean fluorescence intensity of 343.4 compared to 278.8 for healthy controls and 
284.5 for RA patients). 
A possible influence of chemokine-receptor expressing T cells might explain the different 
trends seen at the mRNA and the protein level. To investigate this influence ofT cells on 
the receptor expression seen at the mRNA level, CD3 expression was assessed using 
RT-PCR. All tested samples showed low CD3 expression as seen in Fig. 3.15, which was 
expected, as even a small CD3+ T cell contamination would be enough to generate a PCR 
product. Interestingly, the T cell contamination varied between healthy controls, RA 
patients and PsA patients. The lowest amount ofT cell contamination was seen for the 
PsA group, which also showed the lowest expression compared to the other groups for 
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CXCR3, CCR2, CCR5 and CCR6 expressiOn. Possible correlation between CD3 
expression (thus T cell contamination) and expression levels of those chemokine 
receptors was therefore analyzed using the Spearman test. The results are shown in 
Fig. 3.16. There were no significant correlations, but PsA patients and healthy controls 
both showed a trend towards positive correlation, while RA patients showed a trend 
towards negative correlation. This varying amount ofT cell contamination in each group 
might also explain some of the differences in chemokine receptor expression seen 
between the groups. However, a positive correlation, which was expected since T cells do 
express all of the investigated chemokine receptors and the CD3 expression seemed to 
parallel the receptor expression, was not seen for the RA group. Also, CD3 expression 
data were not obtained for all the patient samples used for RT-PCR analysis of 
chemokine receptor expression therefore limiting the significance of the correlation data. 
Generally, the lack of significant differences in chemokine receptor expression might be 
explained by the high variance seen as it complicated analysis for both RT-PCR and flow 
cytometry. This was especially seen for receptors with low expression such as CCRI, 
CCR2 and CCR5. The RT-PCR results show that the healthy controls were the group 
with the highest variance for these low-expressing receptors. At the protein level, CCRI 
and CCR5 showed variance in the number of receptor expressing B cells especially for 
PsA and RA patients. CCR6 showed variance for all groups for both the number of 
expressing B cells and the amount of expressed receptor. The amount of expressed 
CXCR3 varied the most for the PsA group. At the protein level, the variance seen for 
each group was often due to one or two samples that appeared to be outliers. This might 
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be indicative of subgroups within the healthy or patient population. The sample 
identification for each of these samples was researched to see if they would show a 
similar chemokine receptor expression pattern. Three PsA patients turned out to be 
responsible for most of the variation seen within the PsA group. However, these patients 
did not match in terms of chemokine receptor expression or clinical parameters such as 
disease severity, treatment, gender or age. The same was seen for the two RA patients 
identified to be responsible for most of the variance in the RA group. 
The fact that the samples analyzed were from a heterogeneous pool of volunteers most 
likely accounts for the observed variance in expression, both at the RNA and the protein 
level. Similar individual variation was seen for flow cytometry data in a publication by 
Henneken et af. (Henneken, Dorner et al. 2005). To reduce variance and the possibility of 
type II error more samples would have to be analyzed. Likewise, calculation of the 
statistical power15 for the trends seen at the protein level between healthy controls and 
PsA patients (using http://www.dssresearch.com/toolkit/default.asp) revealed a moderate 
power of 73.1% for CXCR4 and only 53% for CXCRJ, consequently suggesting that 
more samples would be needed to detect a significant expression difference for both 
receptors. However, an increase in number of analyzed samples was not possible for all 
the chemokine receptors. This was due to limited blood sample quantities as the volume 
of blood available was restricted and some patients presented with a decreased number of 
PBMC. The sample volume was especially problematic for RT-PCR, because for this 
15 Statistical power is the ability of a statistical test to detect a difference, g iven that the difference actually 
exists 
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analysis the CD 19+ B cells were separated from the remaining PBMC and as B cells only 
comprise about 3-11% of the total PBMC population (K. Zipperlen, personal 
observation) RNA availability was limited. 
Comparing the chemokine receptor expression only at the total B cell level might also 
explain the lack of differences in receptor expression seen between the three groups. 
Differences in expression of B cell subsets such as memory B cells might have been 
diluted out since the majority of peripheral blood B cells are recirculating naYve B cells. 
Despite the lack of a significant differential expression of chemokine receptors on 
peripheral blood B cells in our study, an increase in inflammatory chemokine receptor 
expression on peripheral blood B cells would be expected in arthritis patients. This would 
allow B cells to migrate to the inflamed joint and would include CXCR3, CCR1, CCR2 
and CCR5. These chemokine receptors are not normally constitutively expressed by B 
cells, but they are receptors for inflammatory chemokines (CXCL9 ligand for CXCR3, 
CCL5 ligand for CCRl and CCR5, CCL2ligand for CCR2) that are found in the synovial 
fluid of the inflamed joints (Konig, Krenn et al. 2000). The CCR6 ligand CCL20 could 
also serve as an attractant for B cells enhancing their migration to the skin as it is 
produced by keratinocytes in lesional psoriatic skin (Homey, Dieu-Nosjean et al. 2000). 
A homeostatic chemokine receptor like CXCR4 could also be expected to be up-
regulated in expression as it has been shown on synovium infiltrating T cells. While not 
all seven investigated chemokine receptors are likely to show increased expression, we 
anticipated to see an increase for some that are important in B cell migration and that 
would be indicative of either a general phenomenon for arthritis patients or a specific 
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feature of PsA patients. This study could only show a trend for an increased expression of 
CXCR4 and CXCR3 for the PsA patient group compared to healthy controls and RA 
patients as determined by flow cytometry. Still, if significant this increased expression for 
CXCR4 and CXCR3 would show the involvement of these receptors in B cell migration 
specifically during PsA pathogenesis. A decreased expression on the other hand for some 
of the chemokine receptors could also be a possibility. This would be a reflection of the 
activation status of the B cell. A down-regulation of CCR6 is seen on activated B cells 
(Krzysiek, Lefevre et a!. 2000) thus it may be possible to see this decreased expression of 
CCR6 on B cells from arthritis patients. This would then indicate the increased number of 
B cells with an activated phenotype. Similarly, decreased expression of CXCR5 is 
observed on activated B cells and after their differentiation into plasma cells (Henneken, 
Dorner et a!. 2005) and would thus also be expected to be seen on B cells from arthritis 
patients. 
Expecting differentially expressed chemokine receptors on lymphocytes migrating to 
specific tissue locations is in line with the endothelial area code model. This model 
implies that lymphocytes regulate their chemokine receptor and adhesion molecule 
profile after activation within secondary lymphoid organs to home to specific tissues 
(Kunkel, Boisvert et a!. 2002; von Andrian and Mempel 2003 ; Burman, Haworth et a!. 
2005). A study by Burman eta!. on the other hand suggests that the chemokine receptor 
expression gets modulated after lymphocytes enter the inflamed synovium (Burman, 
Haworth et a!. 2005). Thus it seems possible that B cells change their chemokine receptor 
expression upon entry into the synovium and therefore it would be less likely to see 
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differences in expression on peripheral B cells. Similarly, activated B cells with an up-
regulated inflammatory chemokine receptor profile might rapidly migrate to sites of 
inflammation therefore not contributing to inflammatory chemokine receptor expression 
of the total B cell population in the periphery. 
Chemokine receptors are important for lymphocyte migration, which was shown here by 
the high expression of homeostatic chemokine receptors CXCR4, CXCR5 and CCR6. 
Also, CXCR3 is expressed by most B cells but in low amounts. However, there does not 
seem to be an involvement of differentially expressed chemokine receptors in recruiting 
peripheral blood B cells to the inflamed joints in patients with arthritis. Trends for 
expression differences were visible for some chemokine receptors but there was high 
individual variation within each group for many of the analyzed receptors thus 
complicating the comparison between PsA patients, RA patients and healthy controls. 
Furthermore, chemokine receptor expression did not correlate with disease status, 
treatment regiments or peripheral blood CD 19+ B cell numbers of individual patients. 
Henneken et al. previously showed up-regulation of CXCR3 and down-regulation of 
CXCR5 and CCR6 by peripheral blood B cells from RA patients, a finding which was 
not reproduced in this study. This difference in results can most likely be explained by 
the fact that a different group of patients and healthy volunteers was used in our study 
(therefore patients with different disease status, medication etc) compared to the study by 
Henneken et al.. 
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Future directions 
Looking at B cell subsets for chemokine receptor expression would provide information 
on receptor expression on activated (memory B cells) and not activated cells (naive B 
cells). This would potentially also aid in interpreting the outliers seen for the chemokine 
receptor expression at the protein level. Most likely activated B cells would show 
differential expression of chemokine receptors to migrate to sites of inflammation in 
contrast to re-circulating na"ive B cells . However, for an optimal study to answer the 
question about the role of chemokine receptors in B cell migration, investigating 
infiltrating B cells in the inflamed joint in addition to peripheral blood B cells would be 
necessary. That way the expression profile of peripheral blood B cells could be put in 
context with the expression seen in the inflan1ed synovium. However, with necessary 
ethical regulations in place to protect the study participants, the accessibility to joint 
biopsies and joint fluid is restricted unless the patient would undergo the procedure for 
needed medical purposes. 
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CHAPTER4 
BAFFIN PSORIATIC ARTHRITIS 
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4.1 INTRODUCTION AND RATIONALE 
The B cell activating factor BAFF is important for B cell activation and survival (see 
Introduction p. 32-34). About 20% of RA patients have elevated serum levels of BAFF 
compared to healthy controls (Cheema, Reschke et al. 2001). A recent presentation at the 
European Academy of Dermatology and Venereology meeting reported an increase in 
serum BAFF levels in psoriasis patients (JEADV 2007, 21, Suppl.l , 15-29). This is 
especially interesting, as psoriasis has so far been perceived as a T cell-mediated disease 
and not much focus has been placed on B cell involvement (Schon and Boehncke 2005). 
Different BAFF antagonists are currently under development and also being used in 
clinical trials for SLE and RA patients (Ramanujam and Davidson 2004). As BAFF can 
influence B cell function in many ways it seems likely that it contributes to an 
exaggerated B cell function in autoimmune diseases by activating and prolonging 
survival of B cells. Similarly, Lesley eta/. concluded from the results of their study using 
monoclonal lg-transgenic mice that under normal circumstances autoreactive B cells 
cannot compete for the limited amounts of BAFF present and are thus eliminated via 
BCR-induced death signals. They hypothesized that elevation of BAFF levels would lead 
to the prolonged survival of autoreactive B cells and therefore enhance pathogenic 
activity (Lesley, Xu et al. 2004). 
BAFF levels also appear elevated in other autoimmune diseases with B cells contributing 
to disease pathology such as SLE and RA. It seems that elevated BAFF levels are 
indicative of a more prominent B cell involvement and help to sustain autoreactive B cell 
survival. Therefore, we hypothesized that if PsA had a B cell component in its 
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pathophysiology, patients may show elevated levels of BAFF. To test this hypothesis 
BAFF levels in plasma from PsA patients as well as RA patients and healthy controls 
were determined using ELISA. 
4.2 RESULTS 
4.2.1 Plasma BAFF levels in PsA and RA patients 
The plasma from 37 PsA patients, 24 RA patients and 35 healthy controls was used for 
BAFF determination by ELISA. As some of these samples were used for the previous 
chemokine study, the information on patients and healthy controls is summarized in 
Chapter 3, Table 3.1. As shown in Fig. 4.1 the mean BAFF levels were similar for the 
three groups with a mean of 970.5 ng/mL ±9 1.6 SEM for RA patients, 989.2 ng/mL 
±47.7 SEM for PsA patients and 841.5 ng/mL ±67.4 SEM for healthy controls. There was 
no significant difference in BAFF levels between the three groups (p = 0.1291 ). BAFF 
levels higher than the mean plus two standard deviations of the healthy control samples 
were considered elevated. Only 2 RA patients had elevated BAFF levels whereas none of 
the PsA patients presented with elevated levels. High variation was seen for the RA 
group with values ranging from 346 ng/mL to 2223 ng/mL and the healthy control group 
(values from 23 1 ng/mL to 1958 ng/mL). 
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Figure 4.1: Plasma BAFF levels in healthy controls, PsA and RA patients. 
This scatter dot plot shows the individual plasma BAFF amounts and the means plus 
SEM in colour for each analyzed group as determined by ELISA. 
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4.2.2 Correlation with clinical parameters and peripheral B cell numbers 
To see whether disease status and treatment had an influence on BAFF levels, 
correlations of BAFF amounts with clinical parameters Goint count, ESR16, RF 17 and 
treatment) were investigated. Information about joint counts, ESR and RF (lgM RF) was 
acquired from patient records. For 16 out of the 37 PsA patients ESR was measured the 
day the blood was taken. Treatment information was obtained from questionnaires filled 
in the same day. BAFF levels from RA and PsA patients were also correlated with 
numbers of peripheral CD19+ B cells, which were determined using flow cytometry 
during the chemokine receptor analysis (double staining for chemokine receptor and 
CD19). 
There appeared to be no correlation between BAFF amounts and disease severity as 
detetmined by joint counts, ESR and RF for both PsA and RA patients (data not shown). 
Analysis of the treatment data showed a positive association of RA patients receiving oral 
steroids and reduced BAFF levels compared to patients not receiving steroid treatment 
(p = 0.0054) as shown in Fig. 4.2 A. This was not seen for PsA patients (Fig. 4.2 B). 
Other treatments (methotrexate, anti-TNF agents) did not reveal associations with BAFF 
levels. 
There was also no correlation between BAFF and the circulating levels of peripheral 
blood B cells for both RA and PsA patients (data not shown). 
16 ESR: Erythrocyte sedimentation rate 
17 only determined for RA patients 
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4.2.3 Comparison of BAFF and chemokine receptor expression levels 
The BAFF levels were also correlated to the chemokine receptor expression of peripheral 
blood B cells, which was reported in Chapter 3. This was done for all three groups and 
the flow cytometry data were used for correlation analysis (percent positive B cells for 
CCRI, CCR and CCR5 and mean fluorescence intensity for CXCR3, CXCR4, CXCR5 
and CCR6) using Spearman's test. The PsA group showed a significant inverse 
correlation between plasma BAFF levels and CXCR4 mean fluorescence intensity and 
CXCR5 mean fluorescence intensity (r = -0.68 with p = 0.0103 and r = -0.66 with 
p = 0.0142 respectively). The results of these correlations are shown in Fig. 4.3. Thus 
PsA patients with low expression of CXCR4 and CXCR5 on peripheral blood B cells 
have higher plasma BAFF levels. No significant correlation was found for the other 
chemokine receptors for the PsA group. Also, there were no significant correlations 
between BAFF levels and chemokine receptor expression for any of the studied 
chemokine receptors for the RA and the healthy control group. 
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4.3 DISCUSSION 
BAFF is an important survival factor for B cells and possibly plays a role in sustaining 
autoreactive B cells (Lesley, Xu et al. 2004). Increased BAFF has been found in the sera 
of patients with rheumatic autoimmune diseases such as SLE and RA (Cheema, Raschke 
et al. 200 I). To see whether BAFF also contributes to autoimmune disease pathology in 
PsA, the plasma BAFF levels in PsA patients were determined using ELISA and 
compared to healthy controls as well as RA patients. 
There was no significant increase in mean BAFF levels for PsA as well as RA patients 
compared to healthy controls. The heterogeneity in BAFF levels seen for all three groups 
in this study has been observed in other studies and has been attributed to individual 
variation of the recruited volunteers (Cheema, Raschke et al. 2001; Matsushita, 
Hasegawa et al. 2006). Also, a similar distribution of plasma BAFF values was seen for 
sample values provided by the supplier of the BAFF ELISA kit (R&D Systems) in the 
package insert, ranging from 609 pg/mL to 1946 pg/mL with a mean of 1000 pg/mL 
(http://www.mdsystems.com/pdf/dblysO.pdf). Another publication studying serum BAFF 
levels in systemic sclerosis noted a range of 390 to 1370 pg/mL serum BAFF for healthy 
participants (Matsushita, Hasegawa et a!. 2006). Thus, the BAFF levels found for the 
healthy participants in our study (231 to 1985 ng/mL) seem to be in accordance with the 
above literature. 
Only two RA patients (8%) had elevated BAFF levels, defining elevated as greater than 
two standard deviations from the mean BAFF level of the healthy controls, compared to 
no patients with elevated BAFF levels in the PsA group. This is in contrast to a study by 
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Cheema et a!. that showed 20% of RA patients with elevated BAFF levels, defining 
elevated as greater than the 951h percentile seen for the healthy controls (Cheema, 
Reschke et a!. 2001 ). This difference might be due to the use of different assay systems 
and individual variations of the different patient population. 
The comparison of BAFF levels with peripheral blood B cell numbers did not reveal any 
correlation for RA as well as PsA patients. Similarly, a study by Can1bridge eta!. showed 
no correlation between BAFF levels and peripheral blood B cell numbers in RA patients 
(Cambridge, Stohl et a!. 2006). Possibly BAFF levels only correlate with peripheral B 
cell numbers when there is a significant reduction of peripheral B cells due to disease or 
depletion therapy. An increase in BAFF levels would then indicate a compensation 
mechanism to replenish the depleted B cell population. Likewise, a strong inverse 
correlation between BAFF levels and peripheral B cell numbers was only observed in RA 
patients upon starting B cell depletion therapy (Cambridge, Stohl et al. 2006). Also, 
BAFF levels did not correlate with clinical parameters such as disease severity (as 
determined by joint counts), ESR and medications for PsA patients. Likewise there was 
no correlation of BAFF levels with joint counts, ESR or rheumatoid factor (lgM RF) for 
the RA patient group. The correlation of BAFF with rheumatoid factor has been 
controversial. A study by Cambridge et a!. (Cambridge, Stohl et a!. 2006) could not 
reproduce the correlation with RF reported in an earlier publication by Cheema et a!. 
(Cheema, Reschke et a!. 2001 ). The lack of correlation seen in our study is in line with 
the data from Cheema et a/. as these authors did not find a correlation with lgM 
rheumatoid factor and BAFF levels (the highest correlation was found with IgG RF) and 
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the only information on RF available for this study was IgM rheumatoid factor (clinical 
testing for RF is performed on the IgM isotype). Generally, the correlation with clinical 
parameters (except patient treatment) was complicated as the information for most of the 
patients on joint counts, ESR and RF was accumulated retrospectively from hospital 
records and not assessed the day the sample was taken. 
Correlating BAFF levels to patient treatment showed the influence of oral corticosteroids 
on BAFF levels in RA patients. There was a significant decrease in BAFF levels for RA 
patients receiving oral steroids compared to RA patients not receiving oral steroids. The 
patients receiving oral steroids were on low dose steroids (< 10 mg/day). This reduction in 
BAFF levels was also observed by others studying Systemic Sclerosis patients receiving 
low dose steroids (5-20 mg/day) (Matsushita, Hasegawa eta!. 2006). However, in a study 
involving SLE patients the influence of steroids on BAFF levels was only seen for high-
dose steroids (>30 mg/day) (Stohl, Metyas et a!. 2003; Matsushita, Hasegawa et a!. 
2006). This influence on BAFF levels by corticosteroid treatment was not seen in the PsA 
patient group despite PsA patients receiving the same or higher doses of steroids 
(however only 35% of PsA patients were on steroid treatment compared to 54% in the 
RA group). The effects of corticosteroids on molecular signalling pathways could 
possibly have a different impact in PsA patients compared to RA patients since PsA has a 
distinct disease pathogenesis. Stohl et a!. hypothesized that BAFF levels in SLE patients 
receiving steroids are reduced because the steroids inhibit interferon (IFN), as IFN-y and 
IFN-a usually up-regulate BAFF expression and are expressed at higher levels in SLE 
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patients (Stohl, Metyas et al. 2003). Thus they concluded that the steroid treatment in 
SLE leads to down-regulation of IFN and subsequently to the down-regulation of BAFF. 
Further comparison of BAFF levels to chemokine receptor expression on peripheral 
blood B cells revealed an inverse correlation between CXCR4 and CXCR5 expression 
and BAFF levels for the PsA group. No correlation was seen for the RA group or healthy 
controls for any of the studied chemokine receptors. So far it is not clear how plasma 
BAFF levels would affect the expression of chemokine receptors on B cells. High BAFF 
levels in patients with a decreased expression of CXCR4 and CXCR5 might be reflecting 
an increase of activated B cells within the total B cell pool. Henneken eta/. investigated 
the downregulation of CXCR5 in their study and found that it occurs on activated B cells 
(Henneken, Dorner et al. 2005). However, information on CXCR4 and CXCR5 
expression on peripheral blood B cells was not available for all the PsA patients with 
high plasma BAFF levels thus reducing the significance of this finding. Further research 
is warranted to investigate the importance of this correlation. 
Future directions 
Despite the lack of a significant difference m plasma BAFF levels between arthritis 
patients and healthy controls, it would be interesting to see whether BAFF levels 
correlate with the activation status of peripheral B cells. Generally comparing BAFF 
levels can be problematic as the BAFF levels found in plasma represent a balance 
between production of BAFF and consumption. Therefore measuring plasma BAFF 
levels might not be indicative of how much BAFF is actually 'seen' by 8 cells. To 
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address this issue the expression of BAFF-R or measuring BAFF RNA expression would 
be necessary. Also, more samples would need to be analyzed to assess the significance of 
the correlation between BAFF levels and chemokine receptor expression. 
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Flow cytometry data 
CXCR3 
mean fluorescence 
Sample Group % positive cells intensity 
KZ055 HC 72.19 160.13 
KZ081 HC 81 .05 125.37 
KZ001 HC 85.25 163.86 
KZ023 HC 77.29 172.65 
KZ006 HC 73.49 117.62 
KZ003 HC 71 .62 108.23 
KZ005 HC 86.06 156.61 
KZ016 HC 78.54 183.49 
KZ032 HC 80.26 141 .81 
KZ053 HC 68.95 100.74 
KZ011 RA 61 .19 151 .60 
KZ028 RA 69.31 140.18 
KZ073 RA 82.97 188.37 
KZ047 RA 89.84 94 .71 
KZ012 RA 71.43 159.56 
KZ078 RA 74.36 124.06 
KZ029 RA 65.14 121.68 
KZ031 RA 61 .88 128.21 
KZ077 RA 83.23 147.87 
KZ079 RA 87.02 88 .28 
KZ008 RA 72.66 163.91 
KZ033 RA 57.11 143.26 
KZ035 RA 57.85 130.38 
KZ083 RA 63.23 157.49 
KZ084 RA 57.95 143.44 
KZ025 PsA 54.46 126.88 
KZ067 PsA 75.40 187.43 
KZ072 PsA 65.35 383.62 
KZ030 PsA 81.43 180.24 
KZ044 PsA 78.51 100.79 
KZ076 PsA 72.78 173.91 
KZ056 PsA 65.56 194.08 
KZ010 PsA 87.13 152.66 
KZ015 PsA 83.54 185.42 
KZ068 PsA 79.08 160.23 
KZ045 PsA 66.25 123.42 
KZ050 PsA 41 .31 150.43 
KZ058 PsA 69.93 215.43 
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CXCR4 
mean fluorescence 
Sample Group % positive cells intensity 
KZ055 HC 88.75 274.19 
KZ081 HC 96.23 298.22 
KZ001 HC 90.59 258.86 
KZ023 HC 90.08 276.44 
KZ006 HC 88.25 263.58 
KZ003 HC 89.25 276.13 
KZ005 HC 90.39 252.88 
KZ016 HC 90.31 351 .61 
KZ032 HC 90.53 242.67 
KZ053 HC 91 .65 293.63 
KZ011 RA 82.95 267.98 
KZ028 RA 95.57 359.44 
KZ073 RA 93.95 242.74 
KZ047 RA 93.18 196.32 
KZ012 RA 92.93 248.13 
KZ078 RA 85.58 216.55 
KZ029 RA 87.85 358.24 
KZ031 RA 94.80 326.60 
KZ077 RA 96.09 352.40 
KZ079 RA 94.08 275.85 
KZ008 RA 88.12 197.05 
KZ033 RA 95.22 320.34 
KZ035 RA 84.90 248.97 
KZ083 RA 93.07 378.81 
KZ084 RA 83.97 277.55 
KZ025 PsA 90.59 390.11 
KZ067 PsA 93.21 413.35 
KZ072 PsA 84.72 235.89 
KZ030 PsA 91 .16 339.29 
KZ044 PsA 94.75 317.26 
KZ076 PsA 91 .09 272.84 
KZ056 PsA 92.49 399.30 
KZ010 PsA 94.73 356.59 
KZ015 PsA 96.82 453.67 
KZ068 PsA 97.12 483.00 
KZ045 PsA 92.64 327.55 
KZ050 PsA 78.16 210.82 
KZ058 PsA 86.03 264.92 
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CXCR5 
mean fluorescence 
Sample Group % positive cells intensity 
KZ055 HC 89.26 340.36 
KZ081 HC 97.33 556.41 
KZ001 HC 97.05 459.65 
KZ023 HC 96.52 635.33 
KZ006 HC 93.39 487.65 
KZ003 HC 96.02 523.14 
KZ005 HC 95.94 513.78 
KZ016 HC 93.40 519.67 
KZ032 HC 95.97 494.95 
KZ053 HC 94.49 584.02 
KZ011 RA 93.16 600.32 
KZ028 RA 93.58 438.51 
KZ073 RA 95.93 353.97 
KZ047 RA 94.95 385.08 
KZ012 RA 98.00 475.00 
KZ078 RA 93.89 497.74 
KZ029 RA 88.39 518.05 
KZ031 RA 93.55 421.66 
KZ077 RA 98.29 567.72 
KZ079 RA 95.01 517.58 
KZ008 RA 93.03 571.58 
KZ033 RA 94.03 514.28 
KZ035 RA 91 .01 407.95 
KZ083 RA 94.78 470.51 
KZ084 RA 90.77 452.63 
KZ025 PsA 89.76 481 .06 
KZ067 PsA 95.22 498.29 
KZ072 PsA 89.74 447.08 
KZ030 PsA 93.79 552.71 
KZ044 PsA 94.85 467.87 
KZ076 PsA 96.50 466.15 
KZ056 PsA 93.72 603.94 
KZ010 PsA 95.92 455.20 
KZ015 PsA 95.20 673.98 
KZ068 PsA 96.88 390.64 
KZ045 PsA 93.50 427.36 
KZ050 PsA 81 .11 370.73 
KZ058 PsA 80.26 356.32 
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Sample Group % positive cells 
KZ055 HC 3.46 
KZ081 HC 1.64 
KZ001 HC 3.63 
KZ023 HC 5.20 
KZ006 HC 3.91 
KZ003 HC 3.18 
KZ005 HC 5.14 
KZ016 HC 3.78 
KZ032 HC 3.96 
KZ053 HC 4.54 
KZ011 RA 2.01 
KZ028 RA 1.62 
KZ073 RA 12.12 
KZ047 RA 4.98 
KZ012 RA 2.64 
KZ078 RA 3.66 
KZ029 RA 3.69 
KZ031 RA 4.34 
KZ077 RA 2.90 
KZ079 RA 5.07 
KZ008 RA 14.01 
KZ033 RA 6.44 
KZ035 RA 1.62 
KZ083 RA 3.88 
KZ084 RA 3.63 
KZ025 PsA 2.35 
KZ067 PsA 6.97 
KZ072 PsA 7.89 
KZ030 PsA 6.77 
KZ044 PsA 2.58 
KZ076 PsA 2.22 
KZ056 PsA 7.00 
KZ010 PsA 3.22 
KZ015 PsA 8.01 
KZ068 PsA 5.03 
KZ045 PsA 3.88 
KZ050 PsA 4.86 
KZ058 PsA 10.69 
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Sample Group % positive cells 
KZ055 HC 4.35 
KZ081 HC 3.88 
KZ001 HC 7.50 
KZ023 HC 10.87 
KZ006 HC 8.08 
KZ003 HC 8.88 
KZ005 HC 30.44 
KZ016 HC 6.39 
KZ032 HC 7.92 
KZ053 HC 5.80 
KZ011 RA 3.36 
KZ028 RA 3.29 
KZ073 RA 22.66 
KZ047 RA 7.20 
KZ012 RA 14.17 
KZ078 RA 5.13 
KZ029 RA 6.33 
KZ031 RA 6.75 
KZ077 RA 2.94 
KZ079 RA 8.58 
KZ008 RA 13.11 
KZ033 RA 8.95 
KZ035 RA 4.63 
KZ083 RA 3.88 
KZ084 RA 4.30 
KZ025 PsA 3.37 
KZ067 PsA 16.10 
KZ072 PsA 15.82 
KZ030 PsA 15.67 
KZ044 PsA 7.04 
KZ076 PsA 6.83 
KZ056 PsA 18.09 
KZ010 PsA 7.24 
KZ015 PsA 15.95 
KZ068 PsA 9.51 
KZ045 PsA 6.46 
KZ050 PsA 6.33 
KZ058 PsA 7.98 
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Sample Group % positive cells 
KZ055 HC 2.04 
KZ081 HC 2.71 
KZ001 HC 3.89 
KZ023 HC 2.78 
KZ006 HC 3.50 
KZ003 HC 2.26 
KZ005 HC 7.05 
KZ016 HC 4.08 
KZ032 HC 5.57 
KZ053 HC 2.63 
KZ011 RA 1.32 
KZ028 RA 2.01 
KZ073 RA 4.38 
KZ047 RA 4.93 
KZ012 RA 1.68 
KZ078 RA 2.10 
KZ029 RA 9.62 
KZ031 RA 0.54 
KZ077 RA 4.37 
KZ079 RA 6.14 
KZ008 RA 10.65 
KZ033 RA 3.72 
KZ035 RA 7.31 
KZ083 RA 6.84 
KZ084 RA 5.60 
KZ025 PsA 1.40 
KZ067 PsA 5.36 
KZ072 PsA 5.64 
KZ030 PsA 4.46 
KZ044 PsA 2.62 
KZ076 PsA 1.26 
KZ056 PsA 2.15 
KZ010 PsA 3.49 
KZ015 PsA 5.42 
KZ068 PsA 6.45 
KZ045 PsA 2.71 
KZ050 PsA 3.54 
KZ058 PsA 11 .22 
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mean fluorescence 
Sample Group % positive cells intensity 
KZ055 HC 91 .38 145.73 
KZ081 HC 94.83 196.60 
KZ001 HC 93.75 201 .74 
KZ023 HC 95.80 237.63 
KZ006 HC 86.76 184.32 
KZ003 HC 92.19 172.68 
KZ005 HC 93.92 210.82 
KZ016 HC 94.10 356.93 
KZ032 HC 93.36 231 .39 
KZ053 HC 87.33 488.09 
KZ011 RA 91 .29 213.32 
KZ028 RA 92.54 190.27 
KZ073 RA 93.59 156.18 
KZ047 RA 94.64 184.86 
KZ012 RA 88.90 167.71 
KZ078 RA 90.80 226.75 
KZ029 RA 83.32 347.46 
KZ031 RA 92.79 257.04 
KZ077 RA 96.07 362.95 
KZ079 RA 90.42 321 .03 
KZ008 RA 81 .21 129.96 
KZ033 RA 93.72 263.54 
KZ035 RA 78.90 97.00 
KZ083 RA 89.63 140.84 
KZ084 RA 85.04 139.06 
KZ025 PsA 91 .01 251 .21 
KZ067 PsA 92.91 155.03 
KZ072 PsA 91.28 172.65 
KZ030 PsA 94.11 251.07 
KZ044 PsA 92.74 284.98 
KZ076 PsA 94.19 190.44 
KZ056 PsA 94.39 284.65 
KZ010 PsA 94.28 247.88 
KZ015 PsA 95.75 511 .04 
KZ068 PsA 93.27 197.09 
KZ045 PsA 89.47 197.73 
KZ050 PsA 65.89 396.97 
KZ058 PsA 76.68 145.64 
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RT-PCRdata 
CXCR3 
Sample Group Ratio 
KZ081 HC 0.082 
KZ055 HC 0.025 
KZ003 HC 0.048 
KZ032 HC 0.099 
KZ053 HC 0.030 
KZ073 RA 0.036 
KZ012 RA 0.070 
KZ077 RA 0.015 
KZ078 RA 0.051 
KZ079 RA 0.014 
KZ072 PsA 0.020 
KZ076 PsA 0.025 
KZ015 PsA 0.015 
KZ067 PsA 0.019 
KZ068 PsA 0.013 
CXCR4 
Sample Group Ratio 
KZ013 HC 1.413 
KZ004 HC 1.391 
KZ026 HC 1.008 
KZ001 HC 1.282 
KZ006 HC 1.129 
KZ028 RA 1.035 
KZ031 RA 1.114 
KZ047 RA 1.270 
KZ011 RA 0.598 
KZ029 RA 0.641 
KZ030 PsA 1.003 
KZ010 PsA 1.201 
KZ044 PsA 1.139 
KZ025 PsA 0.554 
KZ056 PsA 1.697 
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CXCR5 
Sample Group Ratio 
KZ026 HC 0.780 
KZ013 HC 0.530 
KZ004 HC 0.650 
KZ006 HC 0.520 
KZ001 HC 0.390 
KZ034 RA 0.720 
KZ028 RA 0.490 
KZ031 RA 0.560 
KZ047 RA 0.530 
KZ030 PsA 0.580 
KZ010 PsA 0.430 
KZ044 PsA 0.320 
KZ056 PsA 0.240 
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Sample Group Ratio 
KZ026 HC 0.010 
KZ013 HC 0.000 
KZ006 HC 0.035 
KZ001 HC 0.026 
KZ081 HC 0.107 
KZ055 HC 0.059 
KZ016 HC 0.023 
KZ032 HC 0.038 
KZ053 HC 0.077 
KZ072 PsA 0.054 
KZ076 PsA 0.038 
KZ015 PsA 0.000 
KZ067 PsA 0.075 
KZ068 PsA 0.030 
KZ030 PsA 0.039 
KZ010 PsA 0.050 
KZ044 PsA 0.053 
KZ056 PsA 0.000 
KZ035 RA 0.057 
KZ028 RA 0.043 
KZ031 RA 0.051 
KZ047 RA 0.055 
KZ073 RA 0.106 
KZ012 RA 0.083 
KZ077 RA 0.069 
KZ078 RA 0.042 
KZ079 RA 0.070 
152 
Sample Group Ratio 
KZ026 HC 0.041 
KZ013 HC 0.007 
KZ023 HC 0.084 
KZ006 HC 0.036 
KZ001 HC 0.314 
KZ004 HC 0.020 
KZ081 HC 0.109 
KZ055 HC 0.032 
KZ016 HC 0.310 
KZ029 RA 0.012 
KZ028 RA 0.045 
KZ031 RA 0.060 
KZ047 RA 0.025 
KZ073 RA 0.159 
KZ012 RA 0.059 
KZ077 RA 0.049 
KZ078 RA 0.088 
KZ079 RA 0.128 
KZ030 PsA 0.015 
KZ010 PsA 0.013 
KZ044 PsA 0.006 
KZ072 PsA 0.041 
KZ076 PsA 0.058 
KZ015 PsA 0.056 
KZ067 PsA 0.075 
KZ068 PsA 0.000 
KZ037 PsA 0.089 
153 
Sample Group Ratio 
KZ026 HC 0.036 
KZ013 HC 0.015 
KZ023 HC 0.025 
KZ006 HC 0.012 
KZ001 HC 0.000 
KZ004 HC 0.003 
KZ081 HC 0.092 
KZ055 HC 0.015 
KZ016 HC 0.069 
KZ029 RA 0.011 
KZ028 RA 0.024 
KZ031 RA 0.042 
KZ047 RA 0.024 
KZ073 RA 0.059 
KZ012 RA 0.059 
KZ077 RA 0.022 
KZ078 RA 0.034 
KZ079 RA 0.048 
KZ030 PsA 0.013 
KZ010 PsA 0.010 
KZ044 PsA 0.007 
KZ072 PsA 0.025 
KZ076 PsA 0.035 
KZ015 PsA 0.019 
KZ067 PsA 0.020 
KZ068 PsA 0.000 
KZ037 PsA 0.000 
154 
Sample Group Ratio 
KZ001 HC 0.070 
KZ013 HC 0.184 
KZ004 HC 0.056 
KZ023 HC 0.321 
KZ006 HC 0.086 
KZ081 HC 0.379 
KZ055 HC 0.245 
KZ016 HC 0.440 
KZ032 HC 0.771 
KZ011 RA 0.020 
KZ029 RA 0.023 
KZ028 RA 0.105 
KZ073 RA 0.436 
KZ012 RA 0.473 
KZ077 RA 0.264 
KZ078 RA 0.514 
KZ079 RA 0.246 
KZ056 PsA 0.000 
KZ025 PsA 0.056 
KZ030 PsA 0.110 
KZ010 PsA 0.281 
KZ072 PsA 0.057 
KZ076 PsA 0.236 
KZ015 PsA 0.333 
KZ067 PsA 0.046 
KZ068 PsA 0.049 
KZ035 PsA 0.113 
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